Non-coding RNAs as master regulators of ferroptosis in cancer: mechanisms and clinical implications Authors: Haoyang Mo, Yao Xie, Hao Zhang, Yunyi Liu, Wantao Wu, Zhiwei Xia, Peng Luo, Zhixiong Liu, Quan Cheng Published: 2026 ABSTRACT AbstractFerroptosis is a non-apoptotic form of cell death characterized by intracellular iron accumulation and the subsequent elevation of cytotoxic lipid peroxides. Various cellular metabolic pathways intricately regulate this process, including redox homeostasis, iron metabolism, lipid metabolism, and other signaling cascades. Increasing evidence substantiates the critical role of ferroptosis in tumorigenesis and cancer therapy. However, our current understanding of numerous mechanisms underlying tumor ferroptosis remains limited. Noncoding RNAs (ncRNAs) provide a new perspective. Several ncRNAs, particularly microRNAs, long noncoding RNAs, and circular RNAs, are being demonstrated to form a comprehensive regulatory network that exerts direct regulation over ferroptosis-related genes or enzymes while indirectly modulating regulatory factors associated with ferroptosis. Strikingly, ncRNAs also serve as crucial mediators orchestrating communication between cancer cells, stromal cells, and immune cells within the tumor microenvironment (TME). Given their substantial potential in tumors and the TME, ferroptosis-related RNAs emerge as promising targets for immunotherapy and overcoming drug resistance. The development of novel nanomedicines for delivering ncRNAs is crucial in advancing antitumor therapy. This review comprehensively elucidates the regulatory mechanisms of ferroptosis-associated ncRNAs across various cancers, sheds light on their functions within the TME, explores their clinical potential to overcome drug resistance, and highlights unresolved questions.Keywords: Ferroptosis, Non-coding RNAs, Tumor microenvironment, Immunotherapy, Drug resistance Introduction In 2012, Dixon hypothesized that ferroptosis is a non-apoptotic form of controlled, iron-dependent cell death mediated by lipid peroxidation [1]. Ferroptosis is a unique cell death mode that differs morphologically and biochemically from other common regulatory cell death (RCDs) [2]. Ferroptosis cells often exhibit a typical necrotic morphology, characterized by mitochondrial shrinkage, reduction or disappearance of mitochondrial cristae, increased mitochondrial membrane density, and outer membrane rupture, which can be observed under an electron microscope [3–5]. Biochemical features include iron accumulation, excessive oxidative destruction of lipids, reduced glutathione (GSH), and inhibited system xc- and glutathione peroxidase 4 (GPX4) [4, 6, 7]. When the metabolic capacity of the ferroptosis defense system is significantly outweighed by cellular actions that promote ferroptosis, ferroptosis occurs [8–11]. Ferroptosis in various diseases impacts the development, progression, management, and prognosis of multiple tumor types [12–14]. The immune system can prevent tumorigenesis through ferroptosis [15]. For example, interferon-γ (IFN-γ) secreted by CD8+ T cells in response to immune checkpoint blockade (ICB) exhibits tumor-suppressive ability by promoting ferroptosis [16]. Several traditional oncogenic and cancer-related signaling pathways have been shown to regulate ferroptosis [17]. Ferroptosis inducer Erastin can block cystine uptake through the xc−system and selectively trigger cell death in cancer cells harboring mutant but not wild-type reactive oxygen species (RAS) [18, 19]. Because it promotes iron abundance in cancer by regulating the levels of transferrin receptors and ferritin, Ras-mitogen-activated protein kinase (MEK) signaling is elevated in cancer cells that are sensitive to ferroptosis [20, 21]. By contributing to the activities of numerous tumor suppressors, including p53, BRCA1-associated protein (BAP1), and MLL4, ferroptosis serves as a natural barrier to cancer genesis [22–24]. Therapy-refractory cancer cells exhibit predictable sensitivity to ferroptosis under specific cellular states [25–28]. The cause is that the metabolism of cancer cells is significantly reprogrammed to accommodate their increased proliferative demands, which frequently results in the emergence of distinctive metabolic traits, such as an enrichment of polyunsaturated fatty acid phospholipids (PUFA-PLs), excess iron, and unbalanced ferroptosis defense mechanisms [29]. These unique changes make the targeted induction of ferroptosis a promising approach for cancer therapy. In preclinical models, combination targeted treatments have demonstrated acceptable tolerance and synergy [30–32]. Since the 21st century, non-coding RNAs (ncRNAs) have attracted significant attention in cellular processes due to their regulatory functions, particularly in tumor cells [33]. In recent years, the identification of numerous ncRNAs linked to ferroptosis has shed light on the molecular mechanisms underlying the modulation of ferroptosis in tumor cells and tumor-associated cells. They can be primarily increased or decreased in tumor cells or the medium of information transmission between tumor cells and other cells. Numerous studies have demonstrated the potential of ncRNAs as tumor markers for early tumor diagnosis, for predicting treatment outcomes, and for assessing patient prognosis. Given existing cancer treatment methods, modulation of ferroptosis by ncRNAs offers a novel approach to cancer therapy. Additionally, it presents a promising strategy for overcoming tumor drug resistance [34, 35]. The discovery of additional therapeutic agents targeting ferroptosis and ncRNAs may further our understanding of cancer pathogenesis and improve patient outcomes. The tumor microenvironment (TME) consists of tumor cells, immune cells, stromal cells, blood vessels, and the extracellular matrix. It is a complex and dynamic entity that plays a crucial role in tumor progression [36]. Ferroptosis in non-tumor cells within the TME has significantly deepened current knowledge of cancer immunity [37]. Antitumor T cells exhibit high sensitivity to ferroptosis, and inducing ferroptosis may potentially affect the function of these antitumor immune cells. On the other hand, immunosuppressive immune cells, such as tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), require the inhibition of ferroptosis to sustain their immunosuppressive effects [35]. Moreover, ferroptosis in tumor cells can influence antitumor immune responses by releasing various signaling molecules [38]. In turn, immune cells can also regulate ferroptosis in tumor cells [16]. ncRNAs play a crucial role in this complex ferroptosis-based crosstalk within the TME. Thus, a comprehensive, in-depth understanding of the role of ncRNAs in the ferroptosis-based regulatory network in the TME is essential for exploring potential therapeutic strategies in cancer treatment. In this article, we recapitulate the core molecular mechanisms of ferroptosis and the advances in ncRNAs that regulate ferroptosis in different cancers. We then decipher the critical role of ferroptosis-related ncRNAs within the TME. Furthermore, we summarize ferroptosis-related cancer therapy and the potential of utilizing ncRNAs to manipulate ferroptosis for tumor therapeutics. Lastly, we discuss the limitations and outline future research directions in ncRNAs and their involvement in ferroptosis. Mechanisms of ferroptosis Regulation of the antioxidant pathway in ferroptosis System Xc−/GSH/GPX4 axis in ferroptosis System Xc−, a key node in the regulatory pathway, is a cystine-glutamate antiporter located in the cell membrane. It consists of two proteins, Solute Carrier Family 7 Member 11 (SLC7A11) and Solute Carrier Family 3 Member 2 (SLC3A2), linked by disulfide bonds. The primary role of System Xc− is to facilitate the transport of extracellular cystine and intracellular glutamic acid across the cell membrane, thereby elevating intracellular cystine levels. Cystine is subsequently converted to cysteine, which then participates in the biosynthesis of glutathione (GSH) [1, 39, 40]. The activity of System Xc− is primarily regulated by the protein SLC7A11. Overexpression of SLC7A11 enhances cellular resistance to ferroptosis by increasing cystine import into cells [41]. In addition, the expression of SLC7A11 is regulated by various transcriptional and epigenetic factors at multiple levels, including activating transcription factor 4 (ATF4), nuclear factor erythroid 2-related factor 2 (NRF2), and p53, among others [42]. In addition to System Xc− inhibitors like erastin and its derivatives, specific anti-cancer therapies have been discovered to induce ferroptosis in tumor cells by inhibiting SLC7A11 [16, 43]. GSH, the cofactor for GPX4, is crucial in maintaining GPX4 activity and providing essential protection against oxidative stress and ferroptosis [44]. The transcription factor NRF2 also exerts significant regulatory control over GSH function. On the one hand, NRF2 regulates SLC7A11 expression, thereby influencing cysteine concentration [45]. On the other hand, NRF2 also affects the expression of critical enzymes involved in GSH synthesis, such as glutathione synthetase (GSS) and glutamate-cysteine ligase (GCL) [46]. GPX4, the central antioxidant component in this regulatory axis, acts as a potent antagonist against various forms of cell death, including ferroptosis. As a selenoprotein, GPX4’s redox activity relies on selenocysteine (Sec) residues [47]. GPX4 utilizes GSH to reduce the peroxidized phospholipids (PLs) as a phospholipid peroxidation inhibitor. However, if GPX4 fails to reduce excessive levels of PLs within cells, it ultimately triggers iron-mediated catalytic reactions, initiating ferroptosis [48]. GPX4 activity is regulated by selenium availability, and a selenium deficiency can increase cellular vulnerability to ferroptosis. Conversely, adequate selenium utilization increases the resistance of cells and tissues to ferroptosis [49]. In addition, the expression of GPX4 is also regulated by various transcription factors, among which NRF2 has been shown to promote the transcription of GPX4. The NRF2/GPX4 signaling axis regulates ferroptosis in multiple diseases, including cancer [50–52]. Moreover, various post-translational protein modification mechanisms of GPX4 are gradually being elucidated. In summary, the GPX4-dependent antioxidant pathway plays a crucial role in regulating ferroptosis. Targeting key components, such as System Xc-, GSH, GPX4, and their associated regulators, offers novel therapeutic strategies for various diseases, particularly cancer, by modulating ferroptosis. FSP1-dependent pathway in ferroptosis The FSP1-CoQ10-NADPH axis, a non-classical redox system, is another critical parallel pathway that regulates ferroptosis independently of glutathione. The initial observation of significant variability in the sensitivity of different tumor cells to GPX4 inhibitor-induced ferroptosis suggests the involvement of additional parallel mechanisms. Subsequently, apoptosis-inducing factor mitochondrial 2 (AIFM2) / ferroptosis suppressor protein 1 (FSP1) were identified as inhibitors of ferroptosis [9, 53]. FSP1 possesses enzymatic activity as an NADH/NADPH-dependent coenzyme Q10 (CoQ10) oxidoreductase. Myristoylation recruits FSP1 to the plasma membrane, enabling the reduction of CoQ10 to CoQ10H2 while consuming NAD(P)H. CoQ10H2, also known as ubiquinol, is an effective lipophilic antioxidant that can capture free radicals and prevent lipid peroxidation. This process contributes to the inhibition of ferroptosis [9, 53, 54]. Besides its involvement in CoQ10 reduction and ferroptosis inhibition, FSP1 has also been found to play a crucial role in inhibiting ferroptosis through the participation of vitamin K and regulation of the endosomal sorting complexes required for transport (ESCRT) pathway [55, 56]. Multiple upstream factors regulate FSP1 and undergo epigenetic modifications. Notably, NRF2 has been identified as a key regulator of FSP1 transcription. Koppula et al. reported that in kelch-like ECH-associated protein 1 (KEAP1)-deficient lung cancer cells, the FSP1-CoQ10 axis is activated through upregulated NRF2 expression, which consequently increases these cells’ radiation sensitivity [57]. Additionally, in KRAS-mutated tumor cells, the NRF2 pathway has been shown to upregulate FSP1, thereby influencing ferroptosis resistance [58]. DNA methylation, N4-acetylcytidine modification, and m6A modification are significant regulatory mechanisms that mediate FSP1’s inhibitory effects on ferroptosis [59]. FSP1 has been identified as a poor prognostic indicator in various malignant tumors. Due to its role in protecting tumor cells from ferroptosis, targeting and inhibiting FSP1 is a crucial novel anticancer strategy to promote ferroptosis. Nakamura et al. recently discovered a novel FSP1 inhibitor, icFSP1, that promotes ferroptosis via phase separation and inhibits tumor growth. The primary function of icFSP1 is to alter the subcellular localization of FSP1, leading to its dissociation from lipid membranes and inducing condensate formation [60, 61]. DHODH-dependent pathway in ferroptosis Dihydroorotate dehydrogenase (DHODH) localizes to the mitochondrial inner membrane, where it exerts its anti-ferroptosis function through a mechanism distinct from cytosolic GPX4 or FSP1 [62]. Mechanistically, DHODH reduces ubiquinone (CoQ) to ubiquinol (CoQH2) during the oxidation of dihydroorotate to orotate, a reaction coupled to the mitochondrial electron transport chain. The generated CoQH2 functions as a potent lipophilic radical-trapping antioxidant that directly suppresses lipid peroxidation in mitochondrial membranes, thereby preventing ferroptosis initiation at this critical subcellular compartment [63]. This mitochondria-specific defense mechanism is particularly important, as mitochondrial lipid peroxidation is a key driver of ferroptosis. The functional significance of DHODH in regulating ferroptosis has been demonstrated by multiple lines of evidence. Genetic inactivation or pharmacological inhibition of DHODH induces extensive mitochondrial lipid peroxidation and selectively triggers ferroptosis in GPX4low cancer cells. In GPX4high cells, DHODH inhibition synergizes with GPX4 inhibitors to overcome ferroptosis resistance. Metabolically, treatment with GPX4 inhibitors results in acute depletion of N-carbamoyl-L-aspartate and accumulation of uridine, highlighting the metabolic rewiring associated with ferroptosis induction. Importantly, supplementation with dihydroorotate attenuates ferroptosis, whereas orotate potentiates cell death, further validating DHODH’s protective role [63]. Beyond its direct antioxidant function, DHODH influences ferroptosis sensitivity through additional metabolic pathways. DHODH inhibition depletes pyrimidine nucleotides, which impairs ribonucleotide reductase (RNR) activity and reduces GSH consumption during dNTP synthesis, paradoxically creating a GSH-sparing effect that may modulate ferroptosis sensitivity in specific contexts [64]. Recent studies also revealed that DHODH inhibition reduces CDP-choline levels, attenuating phosphatidylcholine synthesis via the Kennedy pathway and promoting the accumulation of polyunsaturated fatty acid-containing phospholipids that are vulnerable to peroxidation [65]. In summary, DHODH represents a spatially distinct, mitochondria-localized mechanism for ferroptosis suppression that complements the cytosolic GPX4 and membrane-associated FSP1 systems. The convergence of DHODH’s roles in pyrimidine metabolism, lipid homeostasis, and mitochondrial redox regulation underscores its multifaceted contribution to ferroptosis resistance, warranting further investigation for cancer therapeutic development [66]. Iron regulation of ferroptosis Iron possesses unique redox properties and participates in various biological processes at both systemic and cellular levels. The orchestration of iron metabolism at the organ level relies on a sophisticated network of tissues, each with a dedicated role. The duodenum is the primary site of dietary iron absorption; enterocytes uptake ferrous iron via divalent metal transporter 1 (DMT1) and export it into the circulation via ferroportin [67]. The liver acts as the central hub for iron storage and distribution, sequestering the bulk of systemic iron as ferritin. Concurrently, it produces hepcidin, the master regulator of systemic iron homeostasis, which controls iron efflux by binding to and inducing the degradation of ferroportin [68, 69]. As a major iron consumer, the bone marrow utilizes most circulating iron for erythropoiesis [70, 71]. Furthermore, splenic macrophages are instrumental in iron recycling, phagocytosing senescent erythrocytes and releasing iron back into circulation, thereby contributing to the daily iron supply [72, 73]. Secondary organs also contribute to iron metabolism. The kidneys contribute to systemic iron metabolism by reclaiming iron-bound proteins such as transferrin and hemoglobin via the megalin-cubilin receptor complexes in proximal tubular cells, thereby maintaining a modest iron reserve [74, 75]. Differential iron distribution at the organ level dictates ferroptosis susceptibility in various tissues. Tissues with elevated iron reserves or increased iron requirements may exhibit enhanced susceptibility to ferroptosis under pathological stress [76]. Tumors from these organs may, in turn, show differential ferroptosis sensitivity, offering therapeutic opportunities. Thus, understanding this physiological context is crucial for deciphering how systemic iron imbalances trigger cellular ferroptosis. Iron-dependent lipid peroxidation is a significant component of ferroptosis, in which regulating iron metabolism by various factors plays a crucial role [77]. Proteins such as transferrin, ferritin, hepcidin, and ferroportin are pivotal in maintaining systemic iron homeostasis [78, 79]. Excessive iron accumulation, particularly in the unstable ferrous iron form, primarily leads to the significant build-up of intracellular reactive oxygen species through the Fenton reaction, thereby promoting ferroptosis [1]. Conversely, iron in forms bound to proteins, such as transferrin or ferritin, can exert a protective effect against ferroptosis [80]. Multiple regulatory factors in iron metabolism and homeostasis can influence cells’ sensitivity to ferroptosis. Cellular iron levels are tightly regulated. Transferrin-bound ferric iron enters cells through transferrin receptor 1 (TFR1)-mediated endocytosis [81]. Within the cells, ferric iron is subsequently reduced to ferrous iron by the six-transmembrane epithelial antigen of prostate 3 (STEAP3). In the cytoplasm, most ferrous iron is oxidized to the ferric form through binding with ferritin, which is stored for later utilization and can be degraded for enzymatic reactions. Ferritin comprises two subunits: ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL). The free ferrous iron in the cytoplasm is stored in the intracellular iron pool and can directly catalyze the formation of free radicals. Intracellular iron levels are primarily regulated by iron regulatory proteins (IRPs), including IRP1 and IRP2. IRPs maintain intracellular iron homeostasis by regulating the translation of TFR1 and FTH1/ FTL under iron-deficient or iron-sufficient conditions [82, 83]. Furthermore, ferritinophagy is another crucial process in regulating iron metabolism, characterized by selective autophagy mediated by nuclear receptor coactivator 4 (NCOA4). NCOA4 is an autophagy receptor regulated by the cellular iron levels. It can mediate the fusion of ferritin with lysosomes, leading to the degradation and release of iron, thereby maintaining intracellular iron homeostasis [84–86]. Based on this, NCOA4-mediated ferritinophagy has also been linked to ferroptosis sensitivity [87]. Mitochondrial iron regulation also closely interacts with ferroptosis. Voltage-dependent anion channels (VDACs) on the outer mitochondrial membrane and membrane transporter mitoferrin (Mfrn)1/2 are critical molecules involved in iron transport into the mitochondria [88, 89]. Mitochondrial iron functions as a cofactor that participates in heme and Fe-S cluster biosynthesis. Iron within mitochondria is highly unstable and tightly regulated by mitochondrial ferritin (FTMT) to prevent ROS accumulation and subsequent mitochondrial dysfunction. The downregulation of FTMT enhances mitochondrial iron accumulation, leading to mitochondrial ROS accumulation and ferroptosis [90, 91]. In conclusion, the cellular systems regulating iron metabolism play a crucial role in ferroptosis. Disruption of intracellular iron homeostasis, particularly one that favors iron overload, is essential in inducing ferroptosis. Lipid regulation in ferroptosis PUFA-containing lipids localized in the cellular membrane are essential drivers of ferroptosis, with the accumulation of lethal lipid peroxides resulting from lipid peroxidation being one of its distinctive hallmarks [92]. PUFAs are the primary targets for lipid peroxidation, and membrane phospholipids containing PL-PUFAs are particularly vulnerable to this oxidative process. As a result, they exhibit higher sensitivity to ferroptosis. Of the various PUFAs, arachidonic acid (AA) and adrenic acid (AdA) take center stage as prominent substrates in the context of lipid peroxidation [93]. This intricate process is governed by key enzymes, including acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3). The activation of AA/AdA occurs through ACSL4, thereby generating AA/AdA-CoA, which LPCAT3 subsequently esterifies to produce AA/AdA-PE. The ensuing oxidation of AA/AdA-PE by lipoxygenases (LOXs) leads to the formation of lipid hydroperoxides (AA/AdA-OOH-PE), further augmenting ferroptosis induction [94, 95]. In the process of ferroptosis, lipid peroxides are converted into alkoxyl radicals in the presence of iron. These radicals subsequently react with adjacent PUFAs, triggering a cascade of lipid-free radicals. ACSL4 in lipid metabolism has been identified as a crucial determinant of ferroptosis sensitivity, exerting its primary influence by directly inhibiting GPX4 [96]. Additionally, it is worth considering that initiation can also occur through non-ACSL4-mediated pathways. Chu et al. discovered the crucial role of arachidonate 12-lipoxygenase (ALOX12) in p53-mediated ferroptosis [97]. They identified the significance of the p53/SLC7A11/ALOX12 pathway in generating lipid peroxides and subsequently inducing ferroptosis. Another member of the acyl-CoA synthetase long-chain family, ACSL3, has an opposite effect to ACSL4. By activating monounsaturated fatty acids (MUFAs), ACSL3 can modify the composition of cell membranes, effectively preventing lipid ROS accumulation in the plasma membrane and conferring protection against ferroptosis [98, 99]. Hence, the competitive interactions between PUFAs and other lipids critically govern the regulatory mechanisms underlying the ferroptosis sensitivity. Replacing PUFAs with MUFAs on membrane phospholipids represents a unique strategy specific tumor cells employ to protect themselves from ferroptosis [100, 101]. Given the elevated lipid metabolism in tumor cells, future endeavors focused on regulating the balance between PUFAs and less susceptible lipids during lipid metabolism, along with modulation of key enzyme activity, hold significant promise for promoting ferroptosis specifically in tumor cells (Fig. 1). Mechanistic diagram of ferroptosis. The upper portion of figure represents normal cells, while the lower portion depicts cells undergoing ferroptosis. Iron metabolism is depicted on the left side of the figure. Proteins are enclosed within the purple oval. The small red circles are Fe3+, while the blue circles are Fe2+. The glutathione peroxidase 4 (GPX4)-dependent ferroptosis defense system is illustrated on the right. Proteins are enclosed within the pink oval box, and molecules are outside the box. The upper and lower sides near the cell membrane depict the process of polyunsaturated fatty acid (PUFA) oxidation accompanied by reactive oxygen species (ROS) production. The enzyme is contained within the gray oval. The mechanism is outlined within the gray rectangular box. The increased transparency indicates the suppressed. In the center of the image, the mitochondria of the ferroptotic cell are atrophied and ruptured. Created with BioRender.com Other pathways in ferroptosis regulation A growing body of research has demonstrated a strong link between p53 and multiple metabolic pathways within ferroptosis, highlighting its crucial role. The current consensus suggests that p53 regulation of ferroptosis can be categorized into canonical and non-canonical pathways [102, 103]. Within the canonical pathway of p53 regulation in ferroptosis, the System Xc−/GSH/GPX4 axis is one of the critical target effectors. Firstly, p53 can suppress SLC7A11 transcription, reducing cystine uptake [24]. Secondly, p53 can target and activate the expression of Glutaminase 2 (GLS2) to enhance glutaminolysis [104]. In addition, p53 regulates phosphoglycerate dehydrogenase and cystathionine β-synthase to limit GSH synthesis [103]. Moreover, p53 can target solute carrier family 25 member 28 (SLC25A28) and ferredoxin reductase (FDXR) to influence iron metabolism and regulate lipid metabolism by modulating ALOX15 activity. These findings highlight the multifaceted role of p53 in regulating ferroptosis [105–107]. In the non-canonical pathway of p53 regulation in ferroptosis, p53 can modulate lipoxygenase family members ALOX12 and ALOXE3 to regulate ferroptosis and mediate tumor suppressive effects [97, 108]. Importantly, regulating the p53-related ferroptosis pathway involves significant involvement of ncRNAs, as discussed in subsequent sections. NRF2, an essential transcription factor in the cellular antioxidant response, modulates lipid peroxidation and ferroptosis through its associated signaling cascade [46]. As previously discussed, NRF2 plays a key role in regulating multiple key enzymes in the antioxidant pathway of ferroptosis. Furthermore, NRF2 plays a vital role in modulating iron and heme metabolism [109]. Among the diverse mechanisms associated with NRF2, the NRF2/Keap1 (Kelch-like ECH-associated protein 1) system is particularly noteworthy. By binding to NRF2, KEAP1 effectively retains it in the cytoplasm, working in conjunction with other ubiquitin ligase complexes to negatively regulate NRF2 expression. The NRF2/KEAP1 system is crucial in maintaining cellular redox homeostasis and protecting cells against oxidative stress [110]. Role of ncRNAs in cancer via the ferroptosis pathway The role of ncRNAs in cancer There are many kinds of ncRNAs, including microRNAs (miRNAs), tRNAs, tRNA-derived small RNAs (tsRNAs), Piwi-interacting RNAs (piRNAs), long non-coding RNAs (lncRNAs), pseudogenes, and circular RNAs (circRNAs). NcRNAs account for most of the human transcriptome [110], once considered inconsequential “junk” transcripts. However, there has been growing recognition of the significant role of ncRNAs in diverse cellular physiological and pathological processes, particularly in tumors [33]. With the advancement of anticancer therapies targeting ncRNAs, the focus on ncRNAs in cancer has increased significantly [111]. NcRNAs play diverse regulatory roles in tumors. Changes in the expression profiles of tumor ncRNAs can not only regulate the division and differentiation of tumor cells and affect tumor malignant progression, but also induce or reverse tumor chemotherapy and radiotherapy resistance [112, 113]. NcRNAs also affect cells in the TME, which indirectly affects tumors. NcRNAs can also act as molecules to transmit information between neighboring cells and distant organs through exosomes and other mechanisms [114]. Interestingly, research has found that exosomes secreted by cardiomyocytes in ischemic heart failure deliver miR-22-3p to tumor cells, thereby reducing their sensitivity to ferroptosis. This finding reveals a potential mechanism by which heart failure increases the risk of cancer [115]. Because ncRNAs play various roles in tumors and possess the advantages of wide distribution, stability, and ease of detection, they can potentially serve as targets for tumor therapy and as biomarkers for early diagnosis and tumor prognosis prediction [116]. Nowadays, many studies explore ncRNAs as targets and tumor biomarkers, but most lack sufficient evidence-based medical evidence and are far from clinical application [117]. NcRNAs regulate cellular activities via various mechanisms, such as epigenetic regulation of gene transcription, post-transcriptional and translational control, and even post-translational modifications [33]. They achieve these functions by directly binding to mRNA or protein or indirectly by regulating other upstream ncRNAs or proteins. Mutations in ncRNAs have also been associated with cancer susceptibility. For example, amplification of the lncRNA FAL1 gene is observed in several types of cancer [118]. Moreover, mutations in ncRNA promoters can directly affect oncogene expression [119]. Recent advancements in ribosome analysis and sequencing technology have enabled scientists to discover translation of ncRNAs, such as the protein-encoding lncRNA LOC90024, indicating that protein translation is also a notable way for ncRNAs to regulate cancer [120, 121]. Modifications to ncRNAs also affect their function [122]. The involvement of ncRNAs in regulating ferroptosis within tumor cells is currently a research hotspot. Over the past few years, an increasing number of studies have revealed the molecular mechanisms underlying the non-coding regulation of ferroptosis in tumor cells/tumor-associated cells. Many ncRNAs related to ferroptosis have been identified, which can predict the efficacy and prognosis of tumor immunotherapy. Harnessing the regulatory potential of ncRNAs to modulate ferroptosis emerges as a promising avenue for cancer therapeutics. Identifying additional therapeutic agents targeting ferroptosis and ncRNAs may further advance our understanding of cancer pathogenesis and improve patient outcomes. However, the regulatory effects of ferroptosis-related ncRNAs are often tissue- and context-dependent: the same ncRNA can exhibit divergent, even opposite, ferroptosis phenotypes across cancer types or disease states. Moreover, ferroptosis sensitivity may diverge between primary tumors and metastases and vary with microenvironmental conditions such as hypoxia and immune infiltration, arguing for context-matched validation when interpreting mechanisms or proposing biomarkers [123–125]. For example, lncRNA H19 appears to exert context-dependent, even opposite, effects on ferroptosis. In lung cancer cells (H1299 and H460), curcumenol induces ferroptosis accompanied by H19 downregulation; H19 overexpression attenuates, whereas H19 knockdown enhances, curcumenol-induced ferroptotic death [126]. Conversely, in primary EGFR-TKI-resistant EGFR-mutant non-small cell lung cancer (NSCLC), β-elemene plus erlotinib upregulates H19, and H19 overexpression increases erlotinib sensitivity with ferroptosis implicated in the combination effect [127]. Beyond lung cancer, breast cancer data further link H19 to ferroptosis through autophagy-associated mechanisms under metformin treatment, supporting the need for context-matched interpretation of H19-centered regulatory networks [128]. In addition to miRNAs, lncRNAs, and circRNAs, there are few studies on other types of ncRNAs in the ferroptosis of tumor cells. However, several studies indicate that different types of ncRNAs may be involved in the ferroptosis of tumor cells. For example, piR-31,470 was found to interact with piwi-like RNA-mediated gene silencing 4 (PIWIL4), leading to the hypermethylation and inactivation of glutathione S-transferase P1 (GSTP1) in prostate cancer [129]. GSTP1 was shown to be a ferroptosis-related gene, suggesting that piR-31,470 may regulate ferroptosis in prostate cancer [130]. We next recapitulate recent advances in understanding the role of ncRNAs in regulating ferroptosis across various cancers. Based on this knowledge, we have compiled Table 1, Fig. 2, and Fig. 3. Given that the existing research on ferroptosis-related ncRNAs predominantly centers around miRNAs, lncRNAs, and circRNAs, our focus is primarily on these three categories of ncRNAs. Table 1ncRNAs associated with ferroptosis in different cancersCancerncRNAsTargetMechanismReferenceBreast cancercircRHOT1miR-106a-5p/STAT3 axisPromote the expression of GPX4 and SLC7A11, inhibit ferroptosis and promote breast cancer.[131]circBGNOTUB1 and SLC7A11Boost the OTUB1-mediated SLC7A11 deubiquitination, inhibit ferroptosis, and promote breast cancer.[132]circGFRA1miR-1228Increase apoptosis-inducing factor mitochondrial-associated 2 (AIFM2) levels, inhibit ferroptosis, and promote breast cancer.[133]circ_0000643miR-153Facilitate SLC7A11, inhibit ferroptosis, and promote breast cancer.[134]lncRNA P53RRARas GTPase-activating protein-binding protein 1 (G3BP1)Boost p53 retention in the nucleus, promote ferroptosis, and inhibit breast canc[135]lncRNA HCP5HCP5-132aaIncrease GPX4, inhibit ferroptosis, and promote breast cancer.[136]lncRNA PTPRG-AS1miR-367c-3pUpregulate SLC7A11, inhibit ferroptosis, and promote triple-negative breast cancer.[137]lncRNA lncFASAperoxiredoxin 1 (PRDX1)Disrupt ROS homeostasis, promote ferroptosis, and inhibit triple-negative breast cancer.[138]mir-324-3pGPX4Downregulate GPX4, promote ferroptosis, and inhibit breast cancer.[139]miR-5096SLC7A11Downregulate SLC7A11, promote ferroptosis, and inhibit breast cancer.[140]Lung cancerexocircRNA-101,093fatty acid-binding protein 3 (FABP3)Increase FABP3 and reduce cellar arachidonic acid (AA), inhibit ferroptosis, and promote lung cancer.[141]circP4HBmiR-1184Increase SLC7A11 expression, inhibit ferroptosis, and promote lung cancer.[142]circDTLmiR-1287-5pIncrease GPX4 expression, inhibit ferroptosis, and promote lung cancer.[143]circSCN8AmiR-1290Facilitate ACSL4, promote ferroptosis, and inhibit LU cancer.[144]circSCUBE3cAMP Response elemence-binding protein (CREB)Inhibit GPX, promote ferroptosis, and inhibit lung cancer.[145]circ_0082374miR-491-5pPromote GPX4, inhibit ferroptosis, and promote lung cancer.[146]lncRNA T-UCR Uc.339miR-339Increase SLC7A11 expression, inhibit ferroptosis, and promote lung cancer.[147]lncRNA H19miR-19b-3pIncrease FTH1 expression, inhibit ferroptosis, and promote lung cancer.[148]LINC00336miR-6852Upregulate the expression of cystathionine-β-synthase (CBS), inhibit ferroptosis, and promote lung cancer.[149]lncRNA P53RRARas GTPase-activating protein-binding protein 1 (G3BP1)Boost p53 retention in the nucleus, promote ferroptosis, and inhibit lung cancer.[135]lncRNA MT1DPmiR-365a-3pDownregulate NRF2, promote ferroptosis, and inhibit lung cancer.[150]lncRNA GSECmiR-101-3pUpregulate CISD1 expression, inhibit ferroptosis, and promote lung cancer.[151]lncRNA ITGB2-AS1FOS-like antigen 2 (FOSL2)Activate the FOSL2/NAMPT axis, inhibit ferroptosis, and promote lung cancer.[152]lncRNA H19miR-19b-3pIncrease FTH1 level, promote ferroptosis, and inhibit lung cancer.[153]lncRNA RGMB-AS1heme oxygenase-1 (HMOX1)Stabilize HMOX1, promote ferroptosis, and inhibit lung cancer.[154]miR-27a-3pSLC7A11Decrease SLC7A11 expression, promote ferroptosis, and inhibit lung cancer.[155]exo-miR-4443METTL3/FSP1Increase the level of FSP1, inhibit ferroptosis and promote lung cancer.[156]miR-34aE2F1/E2F3Decreased the expression of E2F1/E2F3, promote ferroptosis and inhibit lung cancer.[157]miR-324-3pGPX4Downregulate GPX4, promote ferroptosis, and inhibit lung cancer.[158]miR-744-5p/miR-615-3pGPX4Downregulate GPX4, promote ferroptosis, and inhibit lung cancer.[159]Prostate cancerFTH1 pseudogenemiR638 et al.Regulate iron metabolism, promote ferroptosis, and inhibit prostate cancer.[160]lncRNA PCAT1c-Myc, miR-25-3pIncrease SLC7A11 expression, inhibit ferroptosis, and promote prostate cancer.[161]miR-7mTOR/SREBP1 pathwaySuppress mTOR/SREBP1 pathway, promote ferroptosis, and inhibit prostate cancer.[162]Gastric cancermiR-125b-5pSTAT3Suppress STAT3 expression, promote ferroptosis, and inhibit gastric cancer.[163]miR-4715-3paurora kinase A (AURKA)Downregulate GPX4, promote ferroptosis, and inhibit gastric cancer.[164]exo-miR-522arachidonate lipoxygenase 15 (ALOX15)Decrease lipid-ROS, inhibit ferroptosis, and promote gastric cancer.[165]miR-375SLC7A11Downregulate SLC7A11, promote ferroptosis, and inhibit gastric cancer.[166]miR-4893pSLC7A11Suppress SLC7A11 expression, promote ferroptosis, and inhibit gastric cancer.[167]miR-221-3pATF3Upregulate GPX4 and HRD1, inhibit ferroptosis, and promote gastric cancer.[168]lncRNA CBSLRYTHDF2 protein and CBS mRNABoost ubiquitination of ACSL4(acyl-CoA synthase long-chain family member 4), inhibit ferroptosis, and promote gastric cancer.[169]lncRNA BDNF-ASFBXW7Boost voltage-dependent anion channels 3 (VDAC3) ubiquitination, inhibit ferroptosis, and promote gastric cancer.[170]lncRNA PMANELAVL1Stabilize SLC7A11 mRNA, inhibit ferroptosis, and promote gastric cancer.[171]lncRNA DACT3-AS1miR-181a-5pIncrease sirtuin 1 (SIRT1), promote ferroptosis, and inhibit gastric cancer.[172]lncRNA-CASC2SOCS2Suppress SLC7A11, promote ferroptosis, and inhibit gastric cancer.[173]circTMEM87AmiR-1276Boost SLC7A11, inhibit ferroptosis, and promote gastric cancer.[174]circRPPH1miR-375Upregulate SLC7A11, inhibit ferroptosis, and promote gastric cancer.[175]circHIPK3miR-508-3pFacilitate SLC7A11 expression, inhibit ferroptosis, and promote gastric cancer.[176]hsa_circ_0008035miR-302aIncrease E2F7, inhibit ferroptosis, and promote gastric cancer[177]Pancreatic cancermiR-139-5pSLC7A11Downregulate SLC7A11, promote ferroptosis, and inhibit pancreatic cancer.[178]miR-3173-5pACSL4Suppress ACSL4, inhibit ferroptosis, and promote pancreatic cancer.[179]lncRNA A2M-AS1poly (rC) binding protein 3 (PCBP3)Regulate iron metabolism, promote ferroptosis, and inhibit pancreatic cancer.[180]LINC00578ubiquitin-conjugating enzyme E2 K (UBE2K)Decrease ubiquitination of SLC7A11, inhibit ferroptosis, and promote pancreatic cancer.[181]LINC02086miR-342-3pUpregulate CA9 expression, inhibit ferroptosis, and promote pancreatic cancer[182]lncRNA MACC1-AS1STK33Facilitate GPX4, inhibit ferroptosis, and promote pancreatic ductal adenocarcinoma[183]Colorectal cancermiR-545transferringRepress transferring, inhibit ferroptosis, and promote colorectal cancer.[184]miR-15a-3pGPX4Decrease GPX4, promote ferroptosis, and inhibit colorectal cancer.[185]miR-539TNF-α-induced protein 8 (TIPE)Decrease GPX4, promote ferroptosis, and inhibit colorectal cancer.[186]miR-148a-3pSLC7A11Suppress SLC7A11, promote ferroptosis, and inhibit colorectal cancer.[187]LINC01606miR-423-5pFacilitate stearoyl-CoA desaturase 1 (SCD1) expression, inhibit ferroptosis, and promote colorectal cancer.[188]lncRNA OTUD6B-AS1tripartite motif 16 (TRIM16)Decrease GPX4, promote ferroptosis, and inhibit colorectal cancer.[189]LINC00239Nrf2Inhibit ubiquitination of Nrf2, inhibit ferroptosis, and promote colorectal cancer.[190]circ0007142miR-874-3pUpregulate glycerophosphodiester phosphordieste-rase domain containing 5 (GDPD5), inhibit ferroptosis, and promote colorectal cancer.[191]circSTILmiR-413Increase SLC7A11, inhibit ferroptosis, and promote colorectal cancer.[192]circRHBDD1ELAV1Increase SCD, inhibit ferroptosis, and promote colorectal cancer.[193]Liver cancerlncRNA SNHG1miR-199a-5p/3pUpregulate Fanconi anemia complementation group D2 (FANCD2)/ glucose-6-phosphate dehydrogenase (G6PD), inhibit ferroptosis, and promote liver cancer.[194]lncRNA DUXAP8SLC7A11Facilitates SLC7A11 palmitoylation, inhibit ferroptosis, and promote liver cancer.[195]lncRNA PVT1miR-214-3pIncrease GPX4, inhibit ferroptosis, and promote liver cancer.[196]lncRNA HULCmiR-3200-5pDecrease activating transcription factor 4 (ATF4), promote ferroptosis, and inhibit liver cancer.[197]LINC01134Nrf2Promote GPX4 expression, inhibit ferroptosis, and promote liver cancer.[198]LncRNA EPS15-AS1epidermal growth factor receptor substrate 15 (EPS15) and aldo-keto reductase family 1 member B1 (AKR1B1)Promote ferroptosis, and inhibit liver cancer.[199]miR‑23a‑3pACSL4Downregulate ACSL4, inhibit ferroptosis, and promote liver cancer.[200]miR-214-3pATF4Decrease ATF4, promote ferroptosis, and inhibit liver cancer.[201]cIARS (hsa_circ_0008367)AlkB Homolog 5 (ALKBH5)Downregulate ALKBH5, promote ferroptosis, and inhibit liver cancer.[202]circIDEmiR-19b-3pUpregulate RNA binding motif single stranded interacting protein 1 (RBMS1), inhibit ferroptosis, and promote liver cancer.[203]circ0060467miR-6805Increase AIFM2 and GPX4, inhibit ferroptosis, and promote liver cancer.[204]Cholangiocarcinomalinc00976miR-3202Boost GPX4, inhibit ferroptosis, and promote cholangiocarcinoma.[205]Cervical cancercircEPSTI1miR-375/409-3P/515-5pIncrease SLC7A11, inhibit ferroptosis, and promote cervical cancer.[206]circLMO1miR-4192Upregulate ACSL4 expression, promote ferroptosis and inhibit cervical cancer.[207]OsteosarcomamiR-1287-5pGPX4Decrease GPX4, promote ferroptosis, and inhibit osteosarcoma.[208]lncSNHG14miR-206Upregulate SLC7A11, inhibit ferroptosis, and promote osteosarcoma.[209]miR-144-3pZEB1Decrease ZEB1, promote ferroptosis, and inhibit osteosarcoma.[210]miR-26b-5pmethionine adenosyltransferase II alpha (MAT2A)Downregulate MAT2A, promote ferroptosis, and inhibit osteosarcoma.[211]Ovarian cancermiR-424-5pACSL4Reduce ACSL4, inhibit ferroptosis, and promote ovarian cancer.[212]Endometrial cancercircRAPGEF5fox-1 homolog 2 (RBFOX2)Regulate the alternative splicing of transferrin receptor protein 1 (TFRC), inhibit ferroptosis, and promote endometrial cancer.[213]lncRNA LINC02936Sine oculis homeobox homolog 1 (SIX1)Upregulate Ceruloplasmin (CP), inhibit ferroptosis, and promote endometrial cancer.[214]GliomamiR-18aALOXE3Boost 12-hydroxyeicosatetraenoic acids (12-HETE) secretion, inhibit ferroptosis and promote glioblastoma.[108]miR-29bGPX7Suppress GPX7, promote ferroptosis, and inhibit glioma.[215]miR-670-3pACSL4Increase ACSL4, promote ferroptosis, and inhibit glioblastoma.[216]lncRNA TMEM161B-AS1miR-27a-3pUpregulate FANCD2/CD44, inhibit ferroptosis, and promote glioma.[217]lncRNA ATXN8OSglutaminase 2 (GLS2)Stabilize GLS2 mRNA, promote ferroptosis, and inhibit glioma.[218]lncRNA PELATONp53 geneBoost SLC7A11 and reduce ACSL4, COX2, inhibit ferroptosis and promote glioma.[219]lncRNA SNAI3-AS1SND1Inhibits mRNA stability of Nrf2, promote ferroptosis, and inhibit glioma.[220]lncRNA DLEU1ZFP36Degrade ATF3 mRNA, inhibit ferroptosis, and promote glioblastoma.[221]lncRNA KB-1460A1.5mammalian target of rapamycin (mTOR)Impact lipid metabolism, promote ferroptosis, and inhibit glioma.[222]circCDK14miR-3938Upregulate PDGFRA expression, inhibit ferroptosis, and promote glioma.[223]circTTBK2miR-761Boost integrin subunit beta 8 (ITGB8), inhibit ferroptosis, and promote glioma.[224]circLRFN5Paired related homeobox 2 (PRRX2)Downregulate of GCH1 before transcription, promote ferroptosis, and inhibit glioblastoma.[225]Multiple myelomamiR-17-5pferroportin (FPN1)Suppress FPN1 expression, inhibit ferroptosis, and promote multiple myeloma.[226]Acute myeloid LeukemiacircKDM4Chsa-let-7b-5pPositively regulate p53, promote ferroptosis, and inhibit acute myeloid leukemia.[227]circZBTB46stearoyl-CoA desaturase 1 (SCD)Boost SCD, inhibit ferroptosis, and promote acute myeloid leukemia.[228]LINC00618lymphoid-specific helicase (LSH)Suppress SLC7A11 expression, promote ferroptosis, and inhibit acute myeloid leukemia.[229]MelanomamiR-130b‑3pgene DKK1Activate the Nrf2/HO-1 pathway, inhibit ferroptosis and promote melanoma.[230]miR-21-3pthioredoxin reductase 1 (TXNRD1)Downregulate TXNRD1, promote ferroptosis, and inhibit acute melanoma.[231]miR-137glutamine transporter SLC1A5Suppress SLC1A5 expression, inhibit ferroptosis and promote melanoma.[232]miR-9glutamic-oxaloacetic transaminase 1 (GOT1)Decrease GOT1 expression, inhibit ferroptosis and promote melanoma.[233]Head and neck cancercircFNDC3BmiR-520d-5pIncrease SLC7A11, inhibit ferroptosis, and promote oral cancer.[234]circPVT1miR-30a-5pOverexpress Frizzled3 (FZD3), inhibit ferroptosis and promote esophageal cancer.[235]circCNOT6LmiR-384Increase FN1, inhibit ferroptosis, and promote papillary esophageal cancer.[236]circKIF4AmiR-1231Upregulate GPX4, inhibit ferroptosis, and promote papillary thyroid cancer.[237]circ0067934miR-545-3pBoost SLC7A11 expression, inhibit ferroptosis, and promote papillary thyroid cancer.[238]circ BCAR3miR-27a-3pUpregulate transportin-1 (TNPO1), promote ferroptosis, and promote esophageal cancer.[239]miR-200Zinc finger E-box-binding homeobox 1 (ZEB1)Decrease ZEB1, inhibit ferroptosis, and promote head and neck cancer.[240]miR-125b-5pSLC7A11Decrease SLC7A11, promote ferroptosis, and inhibit tongue cancer.[241]lncRNA BBOX1-AS1miR-513a-3pBoost expression of SLC7A11, inhibit ferroptosis, and promote papillary esophageal cancer.[242]circOMA1miR-145-5pIncrease glutamate-cysteine ligase, modifier subunit (GCLM), inhibit ferroptosis, and promote prolactinoma[243]Renal cancermiR-4735-3pSLC40A1Suppress SLC40A1, promote ferroptosis, and inhibit renal cancer.[244]miR-324-3pGPX4Downregulate GPX4, promote ferroptosis, and inhibit renal cancer.[245]lncRNA SLC16A1-AS1miR-143-3pIncrease SLC7A11, inhibit ferroptosis, and promote renal cancer.[246]Bladder cancerlncRNA RP11-89miR-129-5pUpregulate PROM2, inhibit ferroptosis, and promote bladder cancer.[247]lncRNA MAFG-AS1poly(rC)-binding protein 2 (PCBP2)Regulate iron metabolism, inhibit ferroptosis, and promote bladder cancer.[248]lncRNA LUCAT1insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1)Stabilize STAT, inhibit ferroptosis, and promote bladder cancer.[249] ncRNAs associated with ferroptosis in different cancers Non-coding RNAs (ncRNAs) that regulate ferroptosis in primary tumors. The ncRNAs in black font inhibit ferroptosis and promote cancer, while those in red font promote ferroptosis and inhibit cancer. Gynecologic tumors are presented with dashed lines, which are tumors that occur only in women. Created with BioRender.com Mechanism of non-coding RNAs (ncRNAs) regulating ferroptosis in tumor cells. Proteins are depicted in black font within oval boxes, with proteins promoting ferroptosis in blue boxes and proteins inhibiting ferroptosis in purple boxes. The proteins in the lower right corner nucleus are transcription factors, and the CDGSH iron sulfur domain 1 (CISD1) in the lower left corner is located on the mitochondrial membrane. Outside the box are molecules, with molecules in black font promoting ferroptosis and in red font inhibiting ferroptosis. The mechanism is depicted inside the purple rectangular box. The ncRNAs in black font inside the purplr oval box represent the ncRNAs promoting the corresponding protein/molecule. In contrast, the ncRNAs in black font inside the blue oval box represent the ncRNAs inhibiting the corresponding protein/molecule. The upper left corner illustrates the process of ncRNAs in exosomes secreted from the cell. Created with BioRender.com Glioma Glioma is the main primary malignant brain tumor, one of the most feared tumors. The WHO classifies gliomas into four grades based on the degree of malignancy, with glioblastoma (GBM) being the highest grade (IV) [250]. Glioma treatment typically involves surgical resection, radiotherapy, chemotherapy, and various comprehensive therapeutic modalities. However, patient response is poor, especially in GBM. Molecular markers have emerged as valuable tools for tailoring personalized treatment strategies and assessing the clinical prognosis of individuals with glioma. Additionally, it is crucial to continually explore novel mechanisms and effective glioma therapies. In 2021, Yang and colleagues revealed that miR-18a silenced ALOXE3 in GBM, thereby boosting 12-hydroxyeicosatetraenoic acid (12-HETE) secretion, leading to resistance to ferroptosis via activation of the Gs-protein-coupled receptor (GsPCR)-PI3K-Akt pathway in an autocrine manner [108]. Another miRNA, miR-29b, was reported to promote ferroptosis by directly post-transcriptionally reducing GPX7 expression [215]. Ferroptosis-related circRNAs also play a crucial role in glioma. CircCDK14 has been shown to promote oncogenic PDGFRA expression by competing with miR-3938, thereby inhibiting ferroptosis in glioma cells [223]. Circ-TTBK2, negatively regulating ferroptosis, was a sponge of miR-761 and induced the impact on integrin subunit beta 8 (ITGB8) [224]. By contrast, circLRFN5 could enhance ferroptosis and suppress GBM by modulating the PRRX2/GCH1 axis, leading to antioxidant tetrahydrobiopterin (BH4) depletion [225]. Temozolomide is the first-line chemotherapy drug for glioma. Several ferroptosis-related lncRNAs that regulate temozolomide resistance have been reported. lncRNA TMEM161B-AS1 reduced Fanconi anemia complementation group D2 (FANCD2) and CD44 by sponging hsa-miR-27a-3p, resulting in inhibited ferroptosis and enhanced temozolomide resistance [217]. MiR-670-3p also facilitated temozolomide resistance by reducing ACSL4-regulated ferroptosis in GBM [216]. Conversely, lncRNA ATXN8OS held the opposite impact on lncRNA TMEM161B-AS1 through regulation via adenosine deaminase acting on RNA (ADAR)/glutaminase 2 (GLS2) pathway [218]. Additionally, research has revealed that cancer-associated fibroblasts (CAFs) can increase lncRNA DLEU1 expression in GBM, and lncRNA DLEU suppresses ferroptosis by binding ZFP36 and facilitating SLC7A11 expression [221]. Additionally, lncRNA PELATON exhibited its ferroptosis-suppressing effect by promoting the expression of SLC7A11 and inhibiting the expression of ACSL4 and COX2 in glioma cells with mutant p53 [219]. LncRNA SNAI3-AS1 has been found to interfere with m6A recognition of Nrf2 mRNA 3’UTR through competitively binding with SND1, reducing the stability of Nrf2 mRNA, thus boosting ferroptosis in glioma [220]. lncRNA KB-1460A1.5 has been reported to induce ferroptosis by affecting lipid metabolism via inhibiting the mTOR/SREBP-1/SCD1 pathway [222]. Some lncRNA biomarkers worth attention for glioma patients have been reported [251]. LncRNAs in glioma play diverse functions that remain to be explored. Head and neck cancer The disfigurement, pain, and psychic stress caused by head and neck cancer could be unbearable, including oral, esophageal, thyroid, and other [252]. Head and neck cancer was the seventh most common cancer worldwide in 2018, especially esophageal cancer [253]. In recent years, attention has been focused on the role of ncRNAs in regulating ferroptosis in head and neck cancer. Several ferroptosis-related lncRNA signatures have been identified that function as prognostic predictors of head and neck cancer [254]. The miR-200 family, which repressed Zinc finger E-box-binding homeobox 1 (ZBE1), attenuated epithelial-mesenchymal transition (EMT) and inhibited ferroptosis in head and neck cancer [240]. For esophageal squamous cell carcinoma (ESCC), Yao et al. revealed that circPVT1, as a sponge of miR-30a-5p, reduced the 5-FU chemosensitivity of ESCC cells by ferroptosis reduction via downregulation of Frizzled3 (FZD3) [235]. Additionally, circCNOT6L was reported to target miR-384 and increase FN1 protein, facilitating ESCC cell proliferation and attenuating ferroptosis [236]. CircBCAR3, as the sponge of miR-27a-3p, which could be induced by hypoxia in ESCC, was found to simultaneously boost progression, invasion, and ferroptosis by upregulating transportin-1 (TNPO1). However, the mechanism of the combined effect remains unclear [239]. LncRNA BBOX1-AS1 is highly expressed in ESCC tissues and can potentially serve as a prognostic marker. Mechanistically, it acts as a sponge of miR-513a-3p to up-regulate SLC7A11 expression and inhibit ferroptosis [242]. In terms of oral squamous cell carcinoma(OSCC), circFNDC3B exerted its function of regulating ferroptosis by targeting miR-520d-5p and suppressing SLC7A11 [234]. Negatively correlated with the Enhancer of Zeste homolog 2 (EZH2), miR-125b-5p regulated ferroptosis by reducing SLC7A11 in tongue squamous cell carcinoma (TSCC) [241]. Regarding thyroid cancer, circ-0067934 repressed ferroptosis and promoted malignant progression via the miR-545-3p/SLC7A11 signaling pathway [238]. CircKIF4A also inhibits ferroptosis in papillary thyroid cancer via the miR-1231/GPX4 pathway [237]. Breast cancer Breast cancer has emerged as the most prevalent cancer and the second leading cause of cancer-related mortality worldwide [253]. Ferroptosis-related genes were found to be highly enriched in tumors with high intratumor heterogeneity [255]. Ferroptosis-related ncRNAs have the potential to become therapeutic targets and biomarkers. Recent studies have revealed a role for circRNAs in the development of breast cancer. Specifically, circRHOT1, circBGN, and circGFRA1 are remarkably upregulated in breast cancer and inhibit ferroptosis, promoting the occurrence and development of breast cancer. CircRHOT1 acts as a sponge for mir-106-5p to inhibit ferroptosis by regulating mir-106-5p / signal transducer and activator of the transcription 3 (STAT3) axis [131]. Another two studies showed that upregulation of circBGN and circRHOT1 in HER2-positive breast cancer cells enhances GSH depletion and inhibits ferroptosis [132, 133]. Research revealed that FOXQ1, a transcription factor, also inhibited ferroptosis by activating the circ_0000643/miR-153/SLC7A11 axis [134]. In addition, lncRNA P53RRA has been identified as a promoter of ferroptosis in both lung and breast cancer cells [135]. Interestingly, Tong et al. discovered that the lncRNA-encoded protein HCP5-132aa, highly expressed in triple-negative breast cancer, exerted carcinogenic effects by increasing GPX4 levels [136]. lncRNA PTPRG-AS1 targets miR-367c-3p to upregulate SLC7A11, thereby inhibiting ferroptosis in triple-negative breast cancer [137]. In contrast, lncRNA lncFASA increases ferroptosis susceptibility in triple-negative breast cancer by driving peroxiredoxin 1 (PRDX1) formation [138]. Some novel ferroptosis-related lncRNA signatures have also been identified, which can precisely predict the prognosis of breast cancer patients and may have therapeutic significance [256, 257]. Notably, certain drugs have been shown to modulate ferroptosis in breast cancer cells by targeting specific ncRNAs. Metformin, a classic drug for treating diabetes, has been found to upregulate miR-324-3p, which, in turn, downregulates GPX4, promotes ferroptosis in breast cancer cells, and mediates its anticancer effect [139]. Meanwhile, metformin can exert therapeutic effects by inducing ferroptosis via the lncRNA H19 [258]. Researchers also found that lidocaine promotes ferroptosis in breast cancer cells by downregulating SLC7A11 expression via the miR-382-5p/SLC7A11 axis [1]. Penicillin can affect breast cancer resistance to drugs such as cisplatin by regulating iron metabolism [259]. Moreover, miR-5096 has been identified as a potential therapeutic agent that promotes ferroptosis in breast cancer cells by downregulating SLC7A11 [140]. Lung cancer Lung cancer stands as the primary cause of cancer death worldwide [253], with NSCLC accounting for more than 80% of cases and becoming increasingly resistant to anticancer drugs [260]. Among NSCLC subtypes, lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most prevalent. Cisplatin is a first-line chemotherapy drug for advanced NSCLC, and cisplatin resistance is a major factor in its poor efficacy. Novel pathways underlying cisplatin resistance in NSCLC patients have been discovered [32]. Exosomal miR-4443 can downregulate METTL3-induced FSP1 in an m6A manner to suppress cisplatin-induced ferroptosis and achieve cisplatin resistance [156]. LncRNA ITGB2-AS exerts this effect by binding to FOSL and activating the FOSL2/NAMPT axis [152]. Conversely, miR-324-3p was demonstrated to reverse cisplatin resistance by suppressing GPX4 expression and inducing ferroptosis [158]. It has also been found that propofol can upregulate miR-744-5p/miR-615-3p to inhibit GPX4 levels, thereby promoting ferroptosis and inhibiting cisplatin resistance in NSCLC [159]. Curcumenol, a newly reported potential anticancer drug, decreases the FTH1 level by targeting lncRNA H19/miR-19b-3p/FTH1 axis to exert its anticancer effect [148]. β-Elemene, when combined with erlotinib, can upregulate lncRNA H19, thereby inhibiting GPX4 and promoting ferroptosis. At the same time, the overexpression of lncRNA H19 can enhance the sensitivity of EFGR-mutant NSCLC to erlotinib [153]. Recent studies have explored the increasing roles of ferroptosis-related lncRNA in lung cancer. Several lncRNAs that inhibit ferroptosis and promote the malignant progression of lung cancer have been identified, which are potential targets for future cancer treatment. Wang and colleagues found that LINC00336 upregulates cystathionine-β-synthase (CBS) expression by sponging miR-6852, thereby inhibiting ferroptosis and promoting malignant progression. ELAV-like RNA-binding protein 1 (ELAVL1) and LINC00336 stabilize and boost each other through transcriptional regulation by direct interaction [149]. Similarly, lncRNA T-UCR Uc.339, which sponged miR-339, was identified to increase SLC7A11 expression and suppress ferroptosis in LUAD [147]. Moreover, lncRNA GSEC was reported to upregulate CISD1 expression, which is negatively associated with ferroptosis, through miR-101-3p sponging. This process subsequently enhances cell proliferation, migration, and invasion capabilities [151]. On the contrary, cytosolic lncRNA P53RRA was found to interact with Ras GTPase-activating protein-binding protein 1 (G3BP1) in the cytoplasm, then facilitates p53 retention in the nucleus and triggers ferroptosis [135]. lncRNA RGMB-AS1 has been reported to interact with heme oxygenase-1 (HMOX1), enhancing its stability and thereby enhancing ferroptosis of NSCLC [154]. lncRNA MT1DP enclosed by folate-modified liposome nanoparticles that regulate miR-365a-3p /NRF2 axis was also found to promote ferroptosis and inhibit NSCLC [150]. Through bioinformatic analysis, lncRNA HCP5, a ferroptosis-related ceRNA, likely contributes to brain neurovascular-related metastases via the miR-17-5p/HOXA7 axis [261]. More ferroptosis-associated lncRNAs in LUAD and LUSC have been reported in recent years, aimed at exploring novel biomarkers [262, 263]. MiRNAs also play critical roles in the progression of lung cancer. Research revealed that miR-27a-3p promotes NSCLC by inhibiting ferroptosis by negatively regulating SLC7A11 [155]. Additionally, miRNAs regulate the development of lung cancer and influence treatment outcomes with drugs and radiotherapy. As mentioned above, ferroptosis-related miRNAs are associated with cisplatin treatment and drug resistance in lung cancer [238, 255]. It has been reported that LF-MF stabilizes p53 protein and enhances miR-34a expression, targeting E2F1/E2F3 and inhibiting iron metabolism to control LUAD [157]. Several circRNAs in lung cancer have been demonstrated to exacerbate its progression in recent years. ExocircRNA-101,093 secreted by LUAD increased the level of ExocircRNA-101,093 in LUAD cells, and it could directly interact with fatty acid-binding protein 3 (FABP3) and upregulate it, resulting in decreased cellular AA and reduced ferroptosis [141]. CircSCUBE3 inhibits GPX4 by competitive binding to the transcription factor cAMP Response Element-binding protein (CREB), thereby promoting ferroptosis in LUAD [145]. CirDTL was identified as an inhibitor of ferroptosis in NSCLC and exerted its effects via the miR-1287-5p/GPX4 axis [143]. Circ_0082374 targeted miR-491-5p to promote GPX4 and inhibit ferroptosis in NSCLC [146]. Contrary to its effect in NSCLS, circSCN8A was found to be a sponge of miR-1290 and induce ferroptosis by boosting ASCL4 expression [144]. Furthermore, circP4HB could downregulate SLC7A11 expression, thereby suppressing ferroptosis [142]. Gastric cancer With a median survival of less than one year, the efficacy of the main treatment methods for gastric cancer (GC) remains unsatisfactory [264]. Resistance to some chemotherapeutic agents has emerged. In recent years, the relationship between ferroptosis and the drug resistance of GC has been increasingly explored. For instance, cisplatin and paclitaxel have been shown to induce miR-522 secretion via activation of the USP7/hnRNPA1 axis, thereby conferring chemoresistance [165]. CircHIPK3 regulates miR-508-3p/Bcl-2/beclin1/SLC7A11 axis, representing another mechanism of cisplatin resistance in GC [176]. Recently, propofol, dexmedetomidine, and levobupivacaine, which are widely used as anesthetics, have demonstrated potential anticancer properties in GC. In particular, propofol was reported to suppress STAT3 expression by enhancing miR-125b-5p transcription, thereby attenuating gastric cancer progression by inducing ferroptosis [163]. Levobupivacaine, a local anesthetic and a novel ferroptosis inducer, can inhibit GC cell growth by regulating the miR-489-3p/SLC7A11 axis [167]. Dexmedetomidine promoted ferroptosis of GC via circ0008035/miR-302a/E2F7 axis [177]. Roles of other ferroptosis-related miRNAs were also reported in GC. Gomaa and colleagues discovered that Aurora kinase A (AURKA), an oncogenic protein that can be suppressed by miR-4715-3p, was negatively correlated with GPX4, suggesting that miR-4715-3p restoration may induce ferroptosis and hold therapeutic potential [164]. However, downregulation of miR-221–3p inhibited the degradation of GPX4 and hydroxy-3-methylglutaryl reductase (HMGCR) via an increase in ATF3, resulting in ferroptosis of GC cells [168]. Another study showed that miR-375 triggers SLC7A11-dependent ferroptosis, thereby impairing the stemness of GC cells [166]. It’s known that CAFs in the TME have a remarkable impact on GC [165, 265]. Zhang and colleagues reported that exosome-miR-522 derived from CAFs in GC could inhibit ALOX15 expression, thereby reducing lipid-ROS levels and suppressing ferroptosis. Furthermore, cisplatin and paclitaxel have been shown to enhance miR-522 secretion by activating the USP7/hnRNPA1 axis, thereby leading to chemoresistance [165]. This study reveals a novel mechanism by which CAFs contribute to the development and progression of GC. Hypoxia is also a common feature of the TME, and recent research has revealed novel mechanisms by which hypoxia affects GC via the ferroptosis pathway [169, 171]. One study found that HIF-1α-induced lncRNA-CBSLR could decrease CBS expression by recruiting the YTHDF2 protein, leading to ACSL4 protein degradation and protecting GC from ferroptosis [169]. Another hypoxia-induced, highly expressed lncRNA, PMAN, in peritoneal metastasis (PM), could promote the accumulation of SLC7A11, thereby suppressing ferroptosis [171]. Conversely, lncRNA-CASC2 can promote GC ferroptosis by inhibiting SLC7A11 [173]. LncRNAs, such as BDNF-AS, have also been found to play a significant role in inhibiting ferroptosis by promoting the ubiquitination of voltage-dependent anion channel 3 (VDAC3) [170]. Moreover, several ferroptosis-related lncRNAs have notable potential for predicting prognosis and therapeutic response in GC [266, 267]. CircRPPH1 was found to enhance the stemness of GC and promote GC by upregulating SLC7A11, which acts as a sponge for miR-375 [175]. Another circRNA, circTMEM87A, inhibits ferroptosis of GC cells by targeting the miR-1276/SLC7A11 axis [174]. Pancreatic cancer Pancreatic cancer is among the most deadly gastrointestinal tumors, ranking seventh in 2020 mortality rates [253, 268]. The 5-year survival rate is approximately 6% (range: 2% to 9%) [268]. Unfortunately, the cause and mechanism of pancreatic cancer remain unclear. Nowadays, more attention is being paid to researching the role of ferroptosis in pancreatic cancer, and it is hoped that effective therapeutic targets can be identified through ferroptosis research. Zhu and colleagues discovered that miR-139-5p, a potential biomarker, was underexpressed in pancreatic cancer and could regulate the PI3K/Akt signaling pathway by suppressing SLC7A11 expression. This led to the inhibition of pancreatic cancer cell proliferation and invasion [178]. Another study reported a novel glycolysis-related LINC02432/has-miR-98–5p/HK2 axis that aids in diagnosis and predicts prognosis [269]. Meanwhile, several ferroptosis-related lncRNAs have been identified [270, 271]. LINC00578 could suppress ferroptosis by decreasing the ubiquitination of SLC7A11 [181]. LINC02086 can act as a sponge for miR-342-3p, upregulating CA9 expression and inhibiting ferroptosis in pancreatic cancer [182]. On the contrary, lncRNA A2M-AS1 promotes ferroptosis through poly (rC) binding protein 3 (PCBP3) related to iron metabolism [180]. Regarding therapy, Gemcitabine is the first-line chemotherapeutic drug for treating pancreatic cancer. However, drug resistance is increasingly severe [272]. lncRNA MACC1-AS1 inhibits the ubiquitination and degradation of STK33. It promotes the accumulation of GPX4, thereby mitigating gemcitabine-induced oxidative damage to tumor cells, resulting in gemcitabine resistance in pancreatic ductal adenocarcinoma [183]. CAFs have been found to promote gemcitabine resistance in pancreatic cancer. After being absorbed by pancreatic cancer cells, the exosomes they secrete can upregulate miR-3173-5p, inhibit ACSL4 synthesis, and thus inhibit ferroptosis, thereby inducing drug resistance [179]. Yang et al. developed an approach to eliminating resistance by inducing ferroptosis in cancer cells [273]. More mechanisms related to ferroptosis in pancreatic cancer need to be uncovered. Liver cancer Currently, liver cancer ranks as the third most common and sixth most common cancer in the world [253]. Primary liver cancer can be divided into hepatocellular carcinoma (HCC) with the highest proportion, intrahepatic cholangiocarcinoma (iCCA), and rare mixed hepatocellular carcinoma and cholangiocarcinoma [274]. In recent years, induction of ferroptosis has shown potential in the treatment of liver cancer [275]. Ferroptosis-related ncRNAs are potential molecular markers and therapeutic targets. The involvement of lncRNAs in liver cancer is pivotal, as they epigenetically regulate ferroptosis in hepatoma cells. The primarily elevated lncRNA SNHG1 promoted the expression of FANCD and glucose-6-phosphate dehydrogenase (G6PD) through sponging miR-199a-5p/3p, thereby inhibiting ferroptosis and promoting the occurrence and progression of HCC. Meanwhile, the levels of lncRNA SNHG1, FANCD, and G6PD can be used to predict the efficacy of immunotherapy and the prognosis of patients [194]. LncRNA HULC has been reported to function as a sponge of miR-3200-5p, promoting ferroptosis by regulating ATF4 [197]. However, Kang et al. found that silencing LINC01134 could enhance oxaliplatin by modulating the Nrf2/GPX4 axis [198]. Moreover, an effective ferroptosis-related nine-lncRNA signature was constructed to predict prognosis and immune response in HCC patients [276]. Regarding miRNAs, miR-214-3p has been reported to enhance erastin-induced ferroptosis by inhibiting ATF4 in hepatoma cells [201]. CircRNAs also have effects on HCC. CircIDE demonstrated the effect of miR-19b-3p/RNA-binding motif single-stranded interacting protein 1 (RBMS1) axis on ferroptosis [203]. Circ0060467 acts as a sponge for miR-6805 to inhibit ferroptosis in hepatocellular carcinoma by increasing AIFM2 and GPX4 [204]. Sorafenib is currently the first-line drug for advanced liver cancer, which can induce ferroptosis. Liu and colleagues revealed a novel mechanism by which sorafenib inhibits HCC by inducing ferroptosis [202]. Sorafenib-induced hsa_circ_0008367 (Ciars) directly interacted with AlkB Homolog 5 (ALKBH5), then blocked ALKBH5-mediated ferroptosis inhibition [202]. However, ferroptosis-inhibiting miR-23a-3p exhibited a sorafenib-resistant effect by targeting and downregulating ACSL4 [200]. Studies have shown that silencing lncRNA DUXAP8 can inhibit SLC7A11 palmitoylation and facilitate its degradation, thereby promoting ferroptosis and reducing sorafenib resistance in HCC [195]. Interestingly, ketamine was found to be a potential anti-cancer drug. Specifically, Ketamine suppressed lncPVT1 transcription, which directly interacted with miR-214-3p, preventing it from acting as a sponge for GPX4, leading to GPX4 downregulation [196]. LncRNA EPS15-AS1 is a potential drug for liver cancer, for it can inhibit epidermal growth factor receptor substrate 15 (EPS15) and aldo-keto reductase family 1 member B1 (AKR1B1) and promote ferroptosis [199]. These findings underscore the significance of lncRNAs and miRNAs in regulating ferroptosis in liver cancer, suggesting that targeting these molecules could be an effective approach to treating this disease. Colorectal cancer Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract, with the third-highest mortality rate among all cancers [253]. A better understanding of the initiation and transformation mechanisms of ferroptosis in CRC is needed to explore alternative therapeutic targets. Epigenetic aberrations and ferroptosis have both been implicated in the malignant progression of CRC and have garnered significant attention [277, 278]. Notably, miRNAs have emerged as key players in CRC, modulating the ferroptosis pathway. Yang and colleagues found that miR-539 directly targeted TNF-α-induced protein 8 (TIPE), leading to the activation of the SAPK/JNK signaling pathway, downregulation of GPX4, and promotion of ferroptosis [186]. Similarly, miR-15a-3p was reported to promote CRC ferroptosis by directly interacting with and repressing the GPX4 gene [185]. miR-148a-3p promoted ferroptosis by targeting the degradation of SCL7A11 [187]. On the other hand, research has shown that miR-545 can inhibit lipid oxidation and iron accumulation, thereby controlling ferroptosis through transferrin [184]. CircRNAs and lncRNAs also play their roles in regulating ferroptosis in CRC. Circ_0007142, which sponges miR-874-3p, has been reported to inhibit ferroptosis via inducing expression of Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) [191]. CircSTIL similarly inhibits ferroptosis via the miR-431/SLC7A11 axis [192]. Meanwhile, circRHBDD1 inhibits ferroptosis in CRC by interacting with ELAV1/SCD mRNA [193]. Several lncRNAs that inhibit ferroptosis in CRC have been revealed. LINC01606 could sponge miR-423-5p and form a positive feedback loop with the Wnt/β-catenin pathway to enhance stearoyl-CoA desaturase 1 (SCD1) expression, leading to reduced ferroptosis [188]. lncRNA OTUD6B-AS1 inhibited CRC radioresistance by stabilizing tripartite motif 16 (TRIM16) and increasing GPX4-mediated ferroptosis [189]. LINC00239, which enhanced Nrf2 stabilization, also inhibited ferroptosis [190]. Additionally, several ferroptosis-related lncRNAs have been developed as prognostic markers for CRC [279, 280]. Gynecologic cancer Gynecologic cancer originates in female reproductive organs, including the cervical, endometrial, ovarian, vaginal, and vulval. Research on ferroptosis-related ncRNAs is primarily focused on cervical, endometrial, and ovarian cancers. Further exploration is required to investigate the involvement of ncRNAs associated with ferroptosis in other types of gynecological cancer. Cervical cancer is a significant health issue and ranks in the top five for female incidence and mortality rates globally [253]. A small proportion of patients have metastases at diagnosis and progress to advanced stages, for which surgical treatment is not effective [281]. circEPSTI1 was a sponge of miR-375, miR-409-3p, and miR-515-5p, thus upregulated SLC7A11 expression and inhibited ferroptosis in cervical cancer [206]. In addition, circLMO1, which is lowly expressed in cervical cancer, represses ACSL4 protein by competing with miR-4192 for binding [207]. The two circRNAs above are potential novel biomarkers for monitoring and treating cervical cancer. Endometrial cancer is also a common gynecologic cancer. CircRAPGEF5 has been revealed to exhibit elevated levels in endometrial cancer [213]. It increased transferrin receptor protein 1 (TFRC) through interacting with Fox-1 homolog 2 (RBFOX2), a splicing regulator. In recent years, an increasing number of studies have focused on ferroptosis in endometrial cancer (EC). NcRNAs play an indispensable role in regulating ferroptosis in EC. CircRAPGEF5, which is primarily elevated in EC, binds with the RNA-binding protein fox-1 homolog 2 (RBFOX2), a splicing regulator, thereby promoting the formation of TFRC with exon-4 skipping, ultimately leading to ferroptosis resistance in EC cells [213]. Additionally, LINC02936 interacts with sine oculis homeobox homolog 1 (SIX1) and recruits it to the ceruloplasmin (CP) promoter, resulting in CP upregulation, inhibition of ferroptosis, and promotion of EC progression [214]. Although ovarian cancer is less commonly found as a malignant gynecologic cancer, it is a highly aggressive mucinous cancer with unclear etiology and a lack of early screening markers and specific symptoms. Meanwhile, the five-year survival rate for diagnosed patients is less than 50% globally [282]. Wang et al. have reported several ferroptosis-related lncRNAs as potential prognostic biomarkers [283]. Moreover, research has revealed the role of miR-424-5p in negatively regulating ferroptosis by directly suppressing ACSL4 translation in ovarian cancer cells [212]. The epigenetic regulation mechanism of ferroptosis in ovarian cancer needs to be elucidated, which will significantly contribute to the screening, diagnosis, and treatment of ovarian cancer. Urinary cancer Urinary cancer includes the kidney, bladder, urethra, and other organs. Kidney cancer and bladder cancer are particularly prevalent, with global incidence rates of 2.2% and 3.0% in 2020, respectively [253]. Advances in exploring the biology of bladder cancer have recently remarkably impacted how it is diagnosed and treated. lncRNA LUCAT1 stabilizes STAT3 by binding to insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), thereby inhibiting ferroptosis in bladder cancer [249]. Luo et al. revealed that lncRNA RP11-89 sponged miR-129-5p and elevated prominin-2 (PROM2), thereby influencing iron export and inhibiting cell cycle arrest in bladder cancer [247]. LncRNA RP11-89 could be a potential therapeutic target [247]. lncRNA MAFG-AS1 can also regulate intracellular iron metabolism by stabilizing iron chaperone poly(rC)-binding protein 2 (PCBP2) thus inhibiting ferroptosis and boosting cisplatin resistance [248]. Moreover, several ferroptosis-related lncRNAs could serve as biomarkers to predict the prognosis of bladder cancer patients [284]. There are many pathological types of kidney cancer, and clear cell renal cell carcinoma (ccRCC) is the primary type of kidney cancer [285]. In recent years, research on the regulation of ncRNA in kidney cancer has made significant progress. MiR-4735-3p has been identified as targeting SLC40A1. Meanwhile, the inhibitor attenuated iron overload and ferroptosis in ccRCC [244]. LncRNA SLC16A1-AS1 held the opposite function with miR-4735-3p to repress ferroptosis by miR-1433p/SLC7A11 signaling [246]. Other ferroptosis-related lncRNAs have been reported to serve as effective prognostic signatures [286]. Yu and colleagues demonstrated that Icariside II (ICS II) exhibits anticancer properties by inducing ferroptosis through the regulation of the miR-324-3p/GPX4 axis, indicating its potential as a therapeutic agent for kidney cancer [245]. More advanced mechanisms of ncRNA regulation of ferroptosis in urinary cancer cells, as well as the development of new anticancer drugs, await exploration. Prostate cancer Prostate cancer has the second-highest incidence among cancers in men [253]. Most patients with prostate cancer experience a prolonged disease course and are frequently diagnosed with locally advanced or metastatic disease [287]. Studies have investigated the mechanisms of traditional Chinese medicine in treating prostate cancer. Icariin combined with curcumin could induce autophagy and ferroptosis in prostate cancer by upregulating miR-7 and regulating the mTOR/SREBP1 pathway [162]. Chan et al. identified the role of multiple FTH1-related pseudogenes in iron regulation. FTH1 pseudogene, a type of ncRNA, can serve as a competing endogenous RNA of miR-638 and many other oncogenic miRNAs, suppressing tumor malignancy via upregulating FTH1 and boosting ferroptosis [160]. Another study showed that lncRNA PCAT1 upregulated SLC7A11 by stabilizing c-Myc and competing with miR-25-3p, thereby blocking ferroptosis [161]. Furthermore, Feng and colleagues established a ferroptosis-related gene prognostic index (FGPI) and identified a target lncRNA PART1 that could promote prostate cancer [288]. The role of ferroptosis-related circRNA and miRNA in prostate cancer, which could contribute to treating patients with prostate cancer, is relatively blank and has yet to be explored. Melanoma Melanoma is a highly aggressive and lethal skin cancer that originates from melanocytes [289]. In recent years, targeted therapy and immunotherapy have made significant progress, but substantial limitations remain [290]. Researchers are actively exploring the potential of ferroptosis to overcome the limitations of existing treatments. MiR-21-3p, loaded onto gold nanoparticles and delivered to melanoma cells, has been shown to enhance lipid ROS generation by repressing TXNRD1 transcription. Increased ROS could promote IFN-γ-induced ferroptosis and enhance the efficacy of anti-PD-1 immunotherapy [231]. Delivery of miR-21-3p loaded onto gold nanoparticles, in synergy with immunotherapy, could be a promising approach. Additionally, the overexpression of miR-137 inhibits SLC1A5, resulting in reduced glutamine uptake and malondialdehyde (MDA) accumulation, ultimately repressing erastin- and RSL3-induced ferroptosis [232]. Liao et al. revealed that the ferroptosis-reducing effect of miR-130b-3p originated from activating the Nrf2/HO-1 pathway by suppressing the expression of the target gene DKK1 [230]. MiR-9 was also reported to inhibit ferroptosis [233]. It impacted ferroptosis by downregulating glutamic-oxaloacetic transaminase 1 (GOT1) [233]. LncRNAs also play a significant role. Ma and colleagues identified five ferroptosis-related lncRNAs to help uveal melanoma patients, and other ferroptosis-related lncRNAs have been found to construct a prognostic model for cutaneous melanoma patients [291, 292]. Further investigation is warranted to explore the role of ncRNAs, particularly circRNAs and lncRNAs, in regulating ferroptosis in melanoma cells. Osteosarcoma Osteosarcoma, a malignant bone tumor predominantly affecting adolescents and children, is associated with high mortality rates and poor prognosis [293]. There is an urgent need to find practical diagnostic markers and therapeutic targets. LncSNHG14, which downregulates miR-206, was reported to confer resistance to nutlin3a, a small molecule inhibitor, by inhibiting ferroptosis through the overexpression of SLC7A11 [209]. In contrast, miRNA-1287-5p and miR-26b-5p can promote osteosarcoma cell ferroptosis by inhibiting GPX4 and methionine adenosyltransferase II alpha (MAT2A), respectively [208, 211]. In addition, exosome-derived miR-144-3p can reduce the synthesis of ZEB1, thereby promoting ferroptosis and inhibiting the proliferation, invasion, and migration of osteosarcoma, indicating the potential of miR-144-3p as a diagnostic marker for osteosarcoma [210]. Also, ferroptosis-related lncRNAs hold promise as prognostic markers and predictors of the immune landscape in osteosarcoma patients [294, 295]. Acute myeloid leukemia As the most common high-mortality leukemia in adults, acute leukemia (AML) is highly heterogeneous regarding genetic and epigenetic features, immunophenotype, and response to therapy [296]. Our understanding of AML molecules and phenotypes has been diverse; however, the pathophysiological mechanisms of AML remain incompletely elucidated [297]. Ferroptotis-related ncRNAs play essential roles in the development and treatment of acute leukemia. Wang et al. reported that LINC00618 accelerated ferroptosis by inhibiting SLC7A11. Additionally, it was demonstrated to promote vincristine-induced ferroptosis [229]. CircZBTB46 inhibited ferroptosis by upregulating SCD and showed potential promise as a molecular marker for diagnosing and staging AML [228]. On the contrary, circKDM4C facilitated ferroptosis in AML through the upregulation of p53 [227]. Ferroptosis-related ncRNAs in tumor microenvironment The vital connection between ferroptosis and TME is receiving much attention and showing promising prospects in the treatment field. Understanding the significance of ferroptosis in immune cells within the TME and its influence on the host’s anti-tumor immune response is critical for elucidating tumor progression, metastasis, and treatment responses across different tumors. We discuss the role of ferroptosis-related ncRNAs in the tumor microenvironment and the crosstalk between tumor cells and non-tumor cells, represented in Figs. 4 and 5. Crosstalk between tumor cells and non-tumor cells. The immunomodulatory effects of ferroptotic cancer cells in the tumor microenvironment (TME) can be divided into immunosuppressive and immunostimulatory effects. Created with BioRender.com Role of ferroptosis-related noncoding RNAs in tumor microenvironment. Ferroptosis-related non-coding RNAs (ncRNAs) exert immunomodulatory roles within the TME. They serve as critical signaling mediators, transmitting the regulatory effects of cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) on ferroptosis in tumor cells, as well as the reciprocal impact of tumor cells on TAM ferroptosis and polarization. Moreover, ncRNAs mediate the effects of T cells and immunotherapy on ferroptosis in tumor cells. Created with BioRender.com Ferroptosis in immune cells Currently, our understanding of the role of ferroptosis in immune cells is limited. Recent studies suggest that CD8+ T cells exhibit heightened sensitivity to ferroptosis compared to tumor cells, which is predominantly characterized by intracellular lipid accumulation and lipid peroxidation [298]. In TME with elevated cholesterol levels, upregulated CD36 expression in CD8 + T cells augments fatty acid uptake, triggering lipid peroxidation and initiating ferroptosis. This process detrimentally affects the anti-tumor efficacy of cytotoxic T cells [299, 300]. In contrast, regulatory T cells (Tregs) with GPX4 deficiency in the TME exhibit excessive lipid peroxide accumulation, leading to heightened susceptibility to ferroptosis. As a result, this impairs the immunosuppressive capacity of Tregs and enhances overall anti-tumor immunity [301]. Tumor-associated macrophages (TAMs) exhibit highly plastic characteristics within the TME. M1-like macrophages exert tumor-suppressive effects, whereas M2-like macrophages possess tumor-promoting capabilities. Modulating the polarization state of TAMs offers a promising avenue for manipulating the immunosuppressive TME. M1 and M2 macrophages exhibit distinct susceptibilities to ferroptosis. M1 macrophages demonstrate enhanced resistance to drug-induced ferroptosis. This is mainly attributed to the higher inducible nitric oxide synthase expression in M1 macrophages [302]. Furthermore, it has been discovered that Fe3O4 nanoparticles can induce iron-mediated cell death in macrophages, resulting in decreased viability and facilitating their polarization toward the M1 phenotype [303]. Myeloid-derived suppressor cells (MDSCs) in the TME act as negative regulators of anti-tumor immunity. Pathologically activated neutrophils (PMNs) and MDSCs have been shown to impede the function of neighboring T cells by releasing oxygenated lipids through ferroptosis [304]. In another study, Zhu et al. identified a notable upregulation of neutral ceramidase and N-acylsphingosine amidohydrolase (ASAH2) in tumor-infiltrating MDSCs in colorectal cancer. ASAH2 can protect MDSCs in the TME from ferroptosis by destabilizing p53. Using ASAH2 inhibitors to induce ferroptosis in MDSCs represents a promising therapeutic approach to impede MDSC accumulation in immunotherapy [305]. Ferroptosis-mediated crosstalk between tumor cells and immune cells The interplay between tumor and immune cells within the TME involves intricate regulation associated with ferroptosis. Numerous studies have demonstrated that the ferroptosis of tumor cells can inhibit tumor growth. Still, some studies have found the opposite conclusion, possibly related to the complex interaction between tumor ferroptosis and immune cells. Tumor cells undergoing ferroptosis can release damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), ATP, and interferons. It is important to note that different types of DAMPs may convey different signals, such as “eat-me” signals or “save-me” signals. These signals attract diverse immune cells to the site of ferroptosis, enabling them to exert their corresponding effects. For macrophages, the 1-steaoryl-2-15-HpETE-sn-glycero-3-phosphatidylethanolamine (SAPE-OOH) on the surface of tumor cells undergoing ferroptosis acts as an “eat me” signal, triggering phagocytosis by targeting the TLR2 membrane receptor on macrophages [306]. Likewise, HMGB1 serves as an additional signaling molecule, with fully reduced HMGB1 (i.e., all thiol groups) acting as an early damage signal that attracts circulating bone marrow cells. At the same time, disulfide HMGB1 acts as a cytokine stimulating the activation of macrophages and neutrophils [307, 308]. Other signaling molecules, including ATP and calreticulin, exhibit comparable characteristics. Specifically, HMGB1 and ATP have been recognized as immunogenic signals in early-stage ferroptotic tumor cells, playing a pivotal role in the maturation of dendritic cells (DCs) [38]. Furthermore, exposure to calreticulin has been shown to have a remarkable effect in facilitating CD8 + T cell infiltration [309]. CAFs are a crucial component of the TME and exhibit significant heterogeneity. In gastrointestinal cancers, ANO1 can promote the recruitment of CAFs and weaken CD8 + T cell-mediated anti-tumor immunity by inhibiting ferroptosis and facilitating TGF-β release. Significantly, this process can be reversed by suppressing ANO1 [310]. In contrast, “save-me” DAMPs have been identified as eliciting immune suppression and contributing to the development of pro-tumorigenic effects. Tumor cells undergoing ferroptosis can produce exosomes enriched with KRAS, facilitating their uptake by macrophages through an AGER-dependent mechanism and promoting polarization towards M2-like macrophages [311]. Moreover, pancreatic tumor cells undergoing ferroptosis secrete an additional product of oxidative DNA damage, namely 8-hydroxyguanosine (8-OHG). The TMEM173/STING-dependent DNA sensor pathway can induce infiltration and activation of TAMs, thereby promoting pancreatic tumorigenesis [312]. HMGB1 has also been discovered to mediate immunosuppressive effects. In the GPX4-deficient hepatocyte ferroptosis, elevated HMGB1 release promotes the infiltration of immunosuppressive MDSCs. Simultaneously, the upregulation of PD-L1 on tumor cells negates CD8+ T cell activation induced by ferroptosis [275]. These dual effects ultimately attenuated anti-tumor immunity. Another notable immunosuppressive factor, prostaglandin E2 (PGE2), is also elevated in ferroptotic tumor cells. PGE2 then impairs the anti-tumor functions of DCs, natural killer (NK) cells, and cytotoxic T cells [313]. Ferroptosis-related ncRNAs in tumor microenvironment Within the TME, exosomes containing ncRNAs serve as important mediators for communication between cancer cells, stromal cells, and immune cells. The mutual regulation of ferroptosis among cells through ncRNAs is receiving increasing attention. By releasing exosomes that carry specific ncRNAs, TAMs can transmit distinct signals and exert regulatory control over ferroptosis in cancer cells. Luo et al. discovered a novel mechanism in cervical cancer in which autocrine IL4/IL13-activated STAT6 upregulates miRNA-660-5p in TAMs. Consequently, miRNA-660-5p is encapsulated within exosomes and conveyed to cancer cells, leading to the suppression of ALOX15 expression and subsequent inhibition of ferroptosis in malignant cells [314]. On the other hand, ncRNA within exosomes derived from cancer cells can exert a tumor-promoting effect by inducing ferroptosis in M1 macrophages, thereby facilitating tumor progression [315]. In addition, ncRNAs actively contribute to establishing the oncogenic microenvironment through the tumor cell-macrophage crosstalk. In prostate cancer, TAMs produce taurine as a metabolic product, which inhibits ferroptosis in tumor cells and activates miR-181a-5p transcription. Consequently, tumor-derived extracellular vesicles enriched in miR-181a-5p are taken up by macrophages, promoting M2 polarization and enhancing taurine secretion, thereby further impacting tumor cells [316]. In this intricate positive feedback loop, miRNAs play a pivotal role in maintaining the immunosuppressive TME. NcRNAs produced by CAFs also play critical roles in orchestrating the TME that promotes tumor invasion. Qi et al. have confirmed that miRNAs derived from CAFs promote tumor chemoresistance by inhibiting ferroptosis [179]. They found that miR-3173-5p derived from CAFs’ exosomes can directly target ACSL4. After being taken up by pancreatic cancer cells, it inhibits ACSL4 and upregulates tumor cell ferroptosis resistance, leading to chemoresistance against Gemcitabine treatment [179]. Similarly, miR-522 derived from CAFs’ exosomes can be upregulated and secreted upon exposure to cisplatin and paclitaxel. Following internalization by gastric cancer cells, it inhibits ALOX15 and reduces lipid-ROS accumulation within the tumor cells. Consequently, developing ferroptosis resistance results in diminished chemosensitivity of gastric cancer tissues [165]. In contrast, the deficiency of CAF-derived exosomal-specific ncRNAs can also impact tumor progression. A CAF-derived lncRNA disheveled binding antagonist can enhance the sensitivity of gastric cancer cells to oxaliplatin treatment by promoting ferroptosis mediated through the miR-181a-5p/SIRT1 axis [172]. In addition, under the stimulation of IFN-γ produced by tumor-infiltrating CD8+ T cells, tumor cells exhibit an upregulated expression of miR-21-3p. This increased miR-21-3p specifically targets TXNRD1, leading to elevated ROS production and ultimately heightening susceptibility to ferroptosis [233]. Additionally, several bioinformatics analyses have revealed a correlation between ferroptosis-related ncRNAs and the infiltration of various immune cells, as well as the impact on specific immune cells within the TME [254]. For example, Yao et al. identified a group of lncRNAs that can target ferroptosis-related genes and interfere with the activation of CD4 + T cells, resulting in poor tumor prognosis [317]. These studies underscore the substantial involvement of the ferroptosis-related ncRNA signature within the TME and its promising implications for adjuvant immunotherapy. Nevertheless, additional mechanistic studies are imperative to illuminate the intricate regulatory mechanisms governing ferroptosis-related ncRNAs in the TME. Potential for treating cancer through the interaction of ferroptosis and ncRNAs Tumor drugs designed based on traditional apoptosis mechanisms (such as apoptosis and autophagy) gradually show resistance [318, 319]. In recent years, the discovery of novel cell apoptosis has provided new ideas for developing anti-tumor drugs. Ferroptosis is one of them. Research has revealed that certain cancer cell lines with a high mesenchymal state exhibit resistance to multiple treatment modalities but are sensitive to ferroptosis [26, 320]. Many studies have shown that, in breast cancer, colorectal cancer, liver cancer, and other cancers, ferroptosis inhibition can induce or promote tumor drug resistance, whereas ferroptosis stimulation can reverse drug-resistant tumors [321–324]. Anti-tumor strategies targeting ferroptosis are being actively developed. Representative ferroptosis inducers can disrupt the cell’s antioxidant defense and lipid peroxidation homeostasis through different targets, ultimately triggering ferroptosis [325, 326]. RSL3 directly inhibits GPX4 [327], whereas erastin and imidazole ketone erastin (IKE) inhibit system Xc⁻ to reduce cystine uptake and deplete GSH, thereby weakening GPX4-dependent detoxification [327]. FINO2 has been reported to directly oxidize iron and indirectly inhibit GPX4 [328]. FIN56 reduces the protein level of GPX4 and weakens the CoQ-related antioxidant capacity [327]. Additionally, iFSP1 blocks the FSP1-CoQ axis, and brequinar inhibits mitochondrial DHODH, perturbing CoQ/CoQH2 cycling in specific contexts [329]. Notably, IKE has shown in vivo antitumor activity when delivered via tumor-targeted platforms that induce ferroptosis in mouse tumor models [330]. Furthermore, recent research has identified several drugs that induce ferroptosis in cancer cells, potentially offering a new approach to cancer treatment. For example, sulfasalazine (SAS) has been shown to induce ferroptosis in many cell lines (HT-1080, Calu-1, etc.) [18]. Additionally, some classic narcotic drugs have been found to promote ferroptosis in cancer and have therapeutic potentials, such as propofol and lidocaine [163, 331]. A ferroptosis-modulating combination therapeutic strategy is a promising approach that has garnered significant attention. Extensive evidence suggests that inducing ferroptosis has the potential to counteract or overcome drug resistance in cancer therapy, including resistance to chemotherapy, radiotherapy, and targeted therapy. Different strategies can modulate resistance by affecting key ferroptosis pathways. In the case of cisplatin-resistant tumors, the use of compounds such as ent-Kaurane diterpenoids, sulfasalazine, erastin, and dihydroartemisinin has demonstrated the ability to induce ferroptosis via pathways that intricately involve GSH, xCT, and iron metabolism, respectively, thereby providing a strategy to overcome chemotherapy resistance [332–334]. Analogously, a curcumin analog can induce ferroptosis by inhibiting GPX4 and increasing ROS accumulation, ultimately reducing resistance to temozolomide treatment in glioblastoma [335]. Fangyuan Li et al. synthesized a ferrous metal-organic framework-based nanoagent (FMN) loaded with siSLC7A11 and doxorubicin to effectively induce ferroptosis and reverse tumor drug resistance [336]. These studies reveal the therapeutic potential of reversing resistance to various tumor therapies by targeting the multifaceted mechanisms of ferroptosis [34, 337–339]. The emerging role of ncRNAs in this context is particularly compelling, as they act as fine-tuners of the ferroptosis network, thereby critically influencing therapeutic resistance. These ncRNAs, summarized in Table 2, serve not only as biomarkers but also as promising therapeutic targets. The link between ncRNAs, ferroptosis suppression, and resistance to various chemotherapeutic agents is now well-established. In GC, exosomal miR-522 derived from CAFs can inhibit ALOX15 expression, leading to decreased lipid-ROS levels and suppression of ferroptosis, thereby conferring chemoresistance [165]. Similarly, in oxaliplatin-resistant GC, a novel metabolic-epigenetic circuit mediated by the lncRNA BASP1-AS1 was identified. This lncRNA activates LDHA to increase lactate production, which triggers the lactylation of PCBP2, ultimately suppressing ferroptosis and maintaining chemoresistance [340]. In pancreatic cancer, miR-3173-5p inhibits the synthesis of ACSL4 to block ferroptosis and induce resistance to gemcitabine [179]. This resistance can also be driven by other ncRNAs, such as the lncRNA MIR4435-2HG, which promotes CSC stemness and gemcitabine resistance via the miR-1252-5p/STAT1 axis; its depletion sensitizes cells to gemcitabine-induced ferroptosis [341]. In esophageal cancer, exosomal miR-130a-3p from cisplatin-resistant cells can disseminate resistance to recipient cells by suppressing the m6A modification of the ferroptosis suppressor FSP1 [342]. Moreover, in advanced intrahepatic cholangiocarcinoma (ICC), the lncRNA PAX8-AS1 reduces the efficacy of gemcitabine and cisplatin by activating the NRF2/GPX4 axis, thereby inhibiting ferroptosis. Notably, combining a GPX4 inhibitor with standard chemotherapy demonstrated superior antitumor efficacy, highlighting a translational opportunity [343]. Radioresistance is another major clinical hurdle where ncRNA-regulated ferroptosis plays a key role. In colorectal cancer (CRC), the lncRNA FTX was found to be upregulated in radioresistant cells. Mechanistically, FTX sponges miR-625-5p, thereby suppressing SLC7A11. Inhibition of the FTX/miR-625-5p/SLC7A11 axis has been shown to induce ferroptosis, disrupt redox balance, and sensitize CRC cells to ionizing radiation [344]. Targeted therapy resistance, particularly to sorafenib in HCC, is frequently associated with evasion of ferroptosis. Several ncRNAs have been implicated in this process. The lncRNA MALAT1, upregulated via m5C methylation in sorafenib-resistant HCC, inhibits ferroptosis by maintaining the stability of SLC7A11 mRNA [345]. Conversely, the liver-specific, lipid metabolism-related lncRNA HNF4A-AS1 is downregulated in resistant cells. Its overexpression reverses resistance by promoting ferroptosis through m6A-mediated degradation of DECR1, thereby increasing intracellular PUFA levels [346]. Furthermore, specific circRNAs have been identified as critical drivers. For example, circRNA-SORE confers sorafenib resistance by stabilizing the antioxidant enzyme GPX4 [347], while another circRNA, circTTC13, upregulates SLC7A11 by sponging miR-513a-5p, also leading to sorafenib resistance [348]. Beyond HCC, in RCC, the lncRNA STX17-DT contributes to axitinib resistance by modulating the stability of IFI6 mRNA, which in turn decreases mitochondrial ROS and attenuates ferroptosis [349]. Importantly, the connection between ncRNAs, ferroptosis, and resistance extends to immunotherapy. In PDAC, a circRNA derived from TRIP12 (cTRIP12) was identified in ferroptosis-resistant tumors. cTRIP12 acts as a protein scaffold, increasing O-GlcNAcylation levels and thereby stabilizing both FTH, which inhibits ferroptosis, and PD-L1, which promotes immunosuppression. Targeting cTRIP12 synergistically enhanced the efficacy of immunotherapy by inducing ferroptosis [350]. Accordingly, ncRNAs may also act as upstream determinants of responsiveness to canonical ferroptosis inducers such as RSL3 and IKE. Many resistance-associated ncRNAs converge on key ferroptosis nodes (e.g., SLC7A11/xCT, GSH metabolism, NRF2, and GPX4), overlapping with the actionable targets of IKE and RSL3. Consistently, RSL3 and erastin are frequently used as pharmacological probes to demonstrate that altering a given ncRNA alters ferroptosis susceptibility, supporting pathway-level crosstalk [351]. However, direct evidence for ncRNA-directed therapeutics combined with RSL3 or IKE, especially in vivo, remains limited. This gap suggests a testable translational concept that targeting resistance-promoting ncRNAs may sensitize tumors to RSL3/IKE-triggered ferroptosis and potentially synergize with chemo-, radio-, or immunotherapy. In summary, a complex network of ncRNAs regulates tumor cells’ sensitivity to ferroptosis, thereby influencing their response to a wide array of therapeutic modalities. Importantly, the interplay between ncRNAs and ferroptosis is highly context-dependent; the same ncRNA can exert disparate functions across cancer types or disease stages, a dynamic further modulated by microenvironmental factors such as hypoxia and immune context. While much of this research remains in the preclinical stage, the therapeutic strategy of selectively modulating ncRNAs to induce ferroptosis offers a novel and highly promising avenue for overcoming tumor treatment resistance. Table 2ncRNAs associated with drug resistance modulating ferroptosisChemotherapeutic DrugsCancer typeNcRNAsFunctionTargets for ferroptosisreferencestemozolomidegliomalncRNA TMEM161B-AS1Enhance resistanceFANCD2 and CD44[217]miR-670-3pEnhance resistanceACSL4[216]cisplatinNSCLCmiR-4443Achieve resistanceFSP1[156]miR-324-3pReverseresistanceGPX4[139]miR-744-5p, miR-615-3pInhibit resistanceGPX4[159]gastric cancermiR-522Facilitate resistanceALOX15[165]circHIPK3Boost resistanceSLC7A11[176]bladder cancerlncRNA MAFG-AS1Boost resistancePCBP2[248]gemcitabinepancreatic cancerlncRNA MACC1-AS1Facilitate resistanceGPX4[183]miR-3173-5pInduce resistanceACSL4[179]sorafenibhepatocellular carcinomalncRNA DUXAP8Enhance resistanceSLC7A11[195] ncRNAs associated with drug resistance modulating ferroptosis lncRNA TME M161B-AS1 Reverse resistance Evidence suggests that ferroptosis is involved in cellular immunity, and it is believed to affect the effectiveness of cancer immunotherapy. Modulating the TME via ferroptosis could emerge as a promising strategy for cancer therapy. Wang et al. engineered exosomes that encapsulate a ferroptosis inducer. These exosomes, derived from M1-type macrophages, can spontaneously home to tumors, augment oxidative stress within tumor cells, and effectively induce ferroptosis. Moreover, they facilitate the conversion of M2-type macrophages to M1-type macrophages, diminish Treg infiltration, and alleviate the immunosuppressive tumor microenvironment [352]. These observations shed light on the transformative potential of combining immune-activated ferroptosis with novel bioengineering techniques for advancing tumor therapeutics. However, critical consideration must be given to the potential risks associated with ferroptosis-based immunotherapy. Evidence indicates that ferroptosis induction may paradoxically upregulate PD-L1 expression [353–355]. This dual effect presents both a challenge and an opportunity: while PD-L1 upregulation might limit the efficacy of ferroptosis-targeted therapy, it provides a strong rationale for combining ferroptosis inducers with ICB. Preclinical studies have evaluated the potential of combination therapy using ferroptosis inducers and immune checkpoint inhibitors [356]. Importantly, ferroptosis inducers should be selected to stimulate anti-tumor immune cells, suppressing those with pro-tumoral activity [357, 358]. Future clinical trials should incorporate biomarker assessments to monitor immune checkpoint dynamics during ferroptosis-based treatments, with adaptive strategies combining ferroptosis inducers and ICB warranting prioritization. NcRNAs associated with ferroptosis are potential biomarkers that could be used to predict drug resistance and a patient’s prognosis, thereby enabling precision treatment [359]. Many researchers have established ferroptosis-related ncRNA prediction models using epidemiological methods, but their clinical application value remains to be further verified [251, 263]. Furthermore, combining ncRNA-induced ferroptosis with other therapeutic approaches shows excellent potential in cancer treatment. Targeting ncRNAs has long been considered a promising therapy to treat not only cancer. There are several main reasons limiting the application of ncRNAs in clinical therapy: the structural instability of ncRNAs, inefficient intracellular delivery, lack of suitable targeted delivery vectors, and the potential for toxic or side effects due to their numerous targets and presence not only in cancer cells [360, 361]. In addition, despite the challenges associated with using ncRNAs, several therapeutic approaches based on ncRNAs have been developed, including exosomes, liposomes, adenovirus vectors, and others. The FDA has approved 11 RNA-based therapies that utilize gene editing to treat various non-neoplastic diseases [360]. However, they all belong to antisense oligonucleotides (ASOs) or siRNAs, and therapies based on other ncRNAs remain to be explored. Cancer nanotherapeutics is an emerging and promising method that can effectively deliver anti-tumor drugs [326, 362]. Drugs based on nanoparticle systems have better cycle half-life, bioavailability, biodistribution, pharmacokinetics, and safety. Not to be ignored, nanoparticles have a distinct advantage in maintaining the synergistic drug ratio in combination therapy [363]. Some drugs, such as CPX-351, a liposomal carrier used in the treatment of myeloid leukemia, are already in Phase Ⅲ clinical trials [364]. Significant advancements have been made in anti-tumor research using nanomaterials that target ferroptosis. Generally, these novel materials can be categorized into two types: iron-based and non-iron-based nanomaterials, with the overarching objective of inducing the Fenton reaction and perturbing cellular redox homeostasis. The mechanisms underlying these ferroptosis-related nanomaterials have been extensively discussed in previous reviews [365, 366]. The integration of ferroptosis-related ncRNAs with innovative nanomaterials is emerging as a novel approach for developing ferroptosis nanodrugs. This form of nanomedicine holds the potential to augment anti-tumor efficacy by modulating crucial proteins involved in ferroptosis mechanisms, thereby heightening tumor cells’ susceptibility to ferroptosis [231, 362, 367]. Additionally, the combined application of nanodrugs that deliver ferroptosis-targeting ncRNAs and other ferroptosis-targeting nanomedicines may achieve enhanced anti-tumor effects [368]. Conclusions and perspectives Ferroptosis, an extensively investigated regulated cell death, has been implicated in various pathological settings, including cancer as well as degenerative and inflammatory disorders. Accordingly, therapeutic modulation of ferroptosis is bidirectional: ferroptosis induction is commonly explored to eliminate cancer cells, whereas ferroptosis inhibition may be desirable to limit oxidative tissue injury in non-malignant diseases such as neurodegenerative disorders and osteoarthritis [369–371]. Importantly, ferroptosis is not uniformly tumor-suppressive and may be pro-tumorigenic in specific contexts. For instance, hypoxia-induced circBCAR3 promotes tumor aggressiveness while enhancing ferroptosis in ESCC [372]. And ferroptotic stress can also align with immunosuppression/immune evasion, metastatic progression, or therapy-induced adaptation in certain settings [373, 374]. Mechanistically, ferroptosis is primarily driven by iron-dependent lipid peroxidation, shaped by iron and lipid metabolism and antioxidant defenses. Additionally, several other cellular signaling pathways contribute significantly to regulating ferroptosis. The modulation of ferroptosis-related genes by ncRNAs has also been extensively reported. Here, we present a comprehensive review and summary of current progress in this field. A variety of ncRNAs, such as miRNAs, lncRNAs, and circRNAs, actively engage in the regulation of ferroptosis-related enzymes or proteins. Moreover, these ncRNAs can indirectly target additional regulatory factors involved in the ferroptosis process. The profound involvement of ncRNAs in ferroptosis offers novel insights into the intricate mechanisms underlying this process. Due to the various limitations of existing cancer therapies, the role of ncRNAs in tumors has received increasing research attention. Targeting ferroptosis-related ncRNAs for tumor therapy holds promise but also presents significant challenges. Given their regulatory role in critical gene expression during ferroptosis, ncRNAs have emerged as potential candidates for gene therapy. When combined with novel drug-delivery methods, the application of ncRNA-based therapeutics to target ferroptosis holds excellent promise for personalized cancer therapy. However, it is essential to note that targeting ferroptosis-related ncRNAs in diverse therapeutic approaches can be a double-edged sword, as current research still has numerous limitations. Firstly, it is essential to establish a more comprehensive understanding of ncRNA regulatory networks. The current research landscape focuses on the associations between miRNAs, lncRNAs, circRNAs, and ferroptosis. However, understanding how other novel ncRNAs, such as piRNAs and small nuclear RNA (snRNAs), regulate ferroptosis remains underexplored. As the emerging roles of these novel ncRNAs in tumors are being established, more attention should be paid to their regulatory roles in the dynamic balance of the ferroptosis process. Secondly, the role of ncRNA-encoding peptides/proteins is gradually revealed in cancer. The translation of ncRNAs provides a new molecular mechanism for the intricate regulatory network within tumor cells [121]. Nevertheless, few studies report the involvement of ncRNA-encoding proteins in ferroptosis. Further investigation is warranted to explore the translation of ncRNAs associated with ferroptosis. Thirdly, the specific mechanisms by which ncRNAs regulate ferroptosis remain poorly understood. On the one hand, multiple similar or distinct ncRNAs may be identified across various tissues or tumors. Identifying tissue-specific ncRNAs is crucial for achieving precise tumor treatment by targeting ferroptosis-related pathways. On the other hand, it is worth considering that ferroptosis-associated ncRNAs can impact multiple types of cell death and various cellular biological processes while actively participating in other crucial pathways. Moreover, ncRNAs themselves exhibit intricate hierarchical regulatory patterns. Hence, in future research endeavors, it is essential to ensure precise targeting of ncRNAs to the ferroptosis pathway while mitigating potential disruptions to other physiological functions. Furthermore, the regulatory role of ncRNAs in the ferroptosis of tumor cells and non-tumor cells within the TME can potentially create new opportunities for ncRNA-based cancer therapy. Exosomal ncRNAs can serve as mediators, facilitating the impact of immune and non-immune cells within the TME to induce ferroptosis in tumor cells. The subsequent release of DAMPs from this process enhances tumor immunogenicity, thereby promoting immune responses. To fully harness the potential of ferroptosis in cancer therapy, it is essential to reduce immune suppression mediated by ferroptosis within the TME and enhance immune cells’ ability to promote ferroptosis in tumor cells. Targeting ferroptosis-related ncRNAs in immunotherapy represents a promising and innovative treatment strategy. Current research has devoted substantial effort to evaluating the therapeutic and prognostic potential of ncRNAs. Specific ncRNAs are being studied as potential biomarkers of tumor treatment response in clinical trials, while there are also ongoing clinical trials of drugs targeting ncRNAs [375, 376]. Nevertheless, it is essential to note that most findings remain confined to preclinical and early clinical stages. Combining ncRNAs with other therapies, such as immunotherapy, to modulate tumor cells is an inspiring approach that could synergistically amplify treatment effects and improve patient prognosis. Although there remains a substantial distance to traverse before targeting ferroptosis-related ncRNAs for tumor treatment can be applied in clinical practice, we anticipate further validation and translational research. Acknowledgements We appreciate Biorender for supporting the material in graphics in this article. Abbreviations 12-hydroxyeicosatetraenoic acids 8-hydroxyguanosine Arachidonic acid Acyl-CoA synthetase long-chain Acyl-CoA synthetase long-chain family member 4 Adrenoic acid Adenosine deaminase acting on RNA Apoptosis-inducing factor mitochondrial 2 Aldo-keto reductase family 1 member B1 AlkB Homolog 5 Arachidonate lipoxygenases Acute leukemia N-acylsphingosine amidohydrolase Antisense oligonucleotide Activating transcription factor 4 BRCA1-associated protein Antioxidant tetrahydrobiopterin Cancer-associated fibroblasts Cystathionine-β-synthase Clear cell renal cell carcinoma Hsa_circ_0008367 Circular RNAs Ubiquinone Ubiquinol Ceruloplasmin Colorectal cancer CAMP Response elemence-binding protein circRNA derived from TRIP12 Molecular patterns Dihydroorotate dehydrogenase Divalent metal transporter 1 ELAV-like RNA-binding protein 1 Epithelial-mesenchymal transition Epidermal growth factor receptor substrate 15 Esophageal squamous cell carcinoma Endosomal sorting complexes required for transport Enhancer of Zeste homolog 2 Fatty acid-binding protein 3 Fanconi anemia complementation group D2 Ferredoxin reductase Ferroptosis-related gene prognostic index Framework-based nanoagent Ferroptosis suppressor protein 1 Ferritin heavy chain 1 Ferritin light chain Mitochondrial ferritin Frizzled3 Ras GTPase-activating protein-binding protein 1 Glucose-6-phosphate dehydrogenase Glioblastoma Gastric cancer GTP cyclohydrolase 1 Glutamate cysteine ligase Glycerophosphodiester phosphodiesterase domain containing 5 Glutaminase 2 Glutaminase 2 Glutamic-oxaloacetic transaminase 1 Glutathione peroxidase 4 Glutathione Gs-protein-coupled receptor Glutathione synthetase Lutathione S-transferase P1 Hepatocellular carcinoma High mobility group 1 Heme oxygenase-1 Hydroxy-3-methylglutaryl reductase degradation Immune checkpoint blockade Intrahepatic cholangiocarcinoma Icariside II Interferon gamma Insulin-like growth factor 2 mRNA binding protein 1 Imidazole ketone erastin Iron regulatory proteins Integrin subunit beta 8 Kelch-like ECH-associated protein 1 Long non-coding RNAs Lysophosphatidylcholine acyltransferase 3 Lung adenocarcinoma Lung squamous cell carcinoma Methionine adenosyltransferase II alpha Malondialdehyde Myeloid-derived suppressor cells Ras-mitogen-activated protein kinase Mitoferrin Myo-inositol oxygenase Micro RNAs Mammalian target of rapamycin Monounsaturated fatty acids Nuclear receptor coactivator 4 Non-coding RNAs Natural killer cells Nuclear factor erythroid 2-related factor 2 Non-small cell lung cancer Oral squamous cell carcinoma Poly(rC)-binding protein 2 Poly (rC) binding protein 3 Piwi-interacting Piwi-like RNA-mediated gene silencing 4 Peritoneal metastasis Peroxidized phospholipids Pathologically activated neutrophils Peroxiredoxin 1 Prominin-2 Paired-related homeobox 2 Polyunsaturated fatty acid phospholipids Polyunsaturated fatty acids Peactive oxygen species Fox-1 homolog 2 RNA binding motif single stranded interacting protein 1 Regulated cell death Ribonucleotide reductase 1-steaoryl-2-15-HpETE-sn-glycero-3-phosphatidylethanolamine Sulfasalazine Stearoyl-CoA desaturase 1 Selenocysteine Sine oculis homeobox homolog 1 Solute carrier family 25 member 28 Solute Carrier Family 3 Member 2 Solute Carrier Family 7 Member 11 Small nucleolar RNAs Small nuclear RNA Signal transducer and activator of transcription 3 Six-transmembrane epithelial antigen of prostate 3 Tumor-associated macrophages Transferrin receptor 1 Transferrin receptor protein 1 TNF-α-induced protein 8 Tumor microenvironment Transportin-1 Regulatory T cells Tripartite motif 16 Tongue squamous cell carcinoma tRNA-derived small RNAs Voltage-dependent anion channels 3 Voltage-dependent anion channels Zinc finger E-box-binding homeobox 1 Authors’ contributions Quan Cheng: Conceptualization, Funding acquisition, Supervision, Writing - review & editing; Peng Luo: Conceptualization, Supervision, Writing - review & editing; Zhiwei Xia: Conceptualization, Funding acquisition, Supervision, Writing - review & editing; Zhixiong Liu: Conceptualization, Funding acquisition, Supervision, Writing - review & editing; Hao Zhang: Data curation, Funding acquisition, Investigation, Writing - original draft, Writing - review & editing; Haoyang Mo: Data curation, Investigation, Visualization, Writing - original draft, Writing - review & editing; Yao Xie: Data curation, Investigation, Visualization, Writing - original draft, Writing - review & editing; Yunyi Liu, Wantao Wu: Data curation, Funding acquisition, Investigation, Writing - review & editing. Funding This work was supported by the National Natural Science Foundation of China (NO. 82372943, 82303610, 82503442), Chongqing Medical Youth Top Talent Program (NO. YXQN202558), Chongqing Youth Innovation Talent Project (NO. CSTB2025YITP-QCRCX0096), The Science and Technology Innovation Program of Hunan Province (NO. 2023RC3074), Key R&D Program of Jiangxi Province (NO. 20243BBI91007), Jiangxi Provincial Health Technology Project (NO. 202510008), Beijing Xisike Clinical Oncology Research Foundation (NO. Y-Gilead2024-PT-0070), Jiangxi Provincial Natural Science Foundation (NO. 20252BAC220048), and Science Foundation of the AMHT Group (NO. 2022YK04). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors have agreed on the contents of the manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Haoyang Mo, Yao Xie and Hao Zhang contributed equally to this work. Contributor Information Zhiwei Xia, Email: xiazhiwei2011@gmail.com. Peng Luo, Email: luopeng@smu.edu.cn. Zhixiong Liu, Email: zhixiongliu@csu.edu.cn. Quan Cheng, Email: chengquan@csu.edu.cn. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.